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Joint replacement surgery leaves many patients with postoperative pain and function
limitations for extensive periods of time after surgery. This research will predict the
likelihood of poor symptomatic recovery following surgery using preoperative patient data,
including data on patient age, sex and comorbidities. The dataset to be analysed is total
hip replacement data collected between 1989 and 2013 at the Royal Adelaide Hospital.
Using the pain and function data collected repeatedly after surgery, longitudinal data
analysis will be explored. The mortality information in the data will be used to explore
the survival probability of patients based on different predictors using survival analysis.
Repeated pain and function outcomes are modelled using mixed-effects modelling. The
joint modelling of both survival and longitudinal models will be developed. Prediction
methods surrounding these models will be compared to help assess the potential benefits
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Total hip replacement (THR) surgery is a procedure in which damaged bone and cartilage
is removed and replaced with prosthetic components. This surgery is often done when
other treatment options do not provide adequate pain relief. After surgery a patient re-
turns for multiple follow-up appointments where their joint pain and function is measured
with a clinician. These measurements are obtained by answering questions about the level
of pain the patient experiences and through a clinician assessing the patient’s range of
motion. Each patient is intended to have multiple follow-ups after surgery; therefore their
pain and function is measured repeatedly through time. This type of data is called longi-
tudinal data as it involves repeated patient measurements after surgery. This is the type
of THR data that we received from the Royal Adelaide Hospital and will be explored in
this thesis.
In this case, the longitudinal data is collected retrospectively as we are using histor-
ical THR data. The dataset contains not only the patient’s repeated pain and function
measurements but also many variables such as age and gender. These variables contain
enough information to help us predict an individual patient’s pain and function at some
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2 Chapter 1. Introduction
point after surgery. For example, if a patient is a particular gender or age this may help
us predict that their pain and function at 24 months after surgery will be poor. Therefore,
we wish to use patient measurements of joint pain and function to predict postoperative
patient pain and function based on preoperative factors, such as age and gender.
The pain and function measure that we use is the Harris hip score (HHS). The HHS is
a clinician-based outcome tool used to evaluate patient recovery following THR surgery
by combining measures of pain and function into a single score [12]. It is a score between
0 and 100, where higher scores are associated with less pain and better function and
lower scores are associated with more pain and reduced function. A HHS of less than 70
is classified as poor pain and function [12]. This score is the combined measurement of
patient pain and function that is used in this study.
We use statistical modelling techniques to determine ways to predict postoperative
patient HHS based on preoperative factors. There are two main modelling techniques
that are explored in this thesis; mixed-effects models and joint models. Mixed-effects
models are a type of statistical model that is used to analyse correlated data, such as
repeated measurements. They include both fixed effects and random effects, where fixed
effects are the parameters associated with an entire population and random effects are the
parameters associated with the individual within the population. The main advantage
of this model is its ability to separate age and cohort effects. This means that it can
distinguish changes over time within patients from differences among patients at the
baseline level. In turn, this model describes the relationship between a response variable,
such as the HHS, and some covariates, such as age and gender.
Along with a longitudinal response variable, this dataset also includes a time-to-event
outcome, patient death. Instead of analysing these two outcomes separately we can anal-
yse them together within a joint model framework. This allows us to account for the
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effect of the HHS, the longitudinal outcome, as a time-dependent covariate. This model
describes the relationship between a longitudinal response variable and some covariates,
as well as the relationship between the hazard of survival and some covariates, including
the longitudinal response variable.
A key difference between this study and previous studies into THR is the use of sub-
jective reports of symptomatic relief and patient satisfaction, namely the HHS [6]. From
the literature, on average between 25% and 50% of patients report persistent postoper-
ative pain and function limitations at one to two years after joint replacement surgery
by which time there should be resolution of symptoms [21, 7]. Within Australia alone
approximately 590,000 THR procedures took place in 2016, and this is only increasing
each year [6]. This is a large number of patients who are not experiencing the expected
results of THR surgery. Therefore, research that focuses on improving symptomatic relief
for patients after THR surgery, by focusing on measures such as the HHS, is crucial. Oth-
erwise, the intended advantages of THR, such as reducing individual, social and health
care burdens, cannot be fully realised.
This study also acknowledges the increased risk of adverse patient outcomes after a
THR due to comorbidity and multi-morbidity, which is not always addressed. Two or
more coexisting medical conditions or diseases that are additional to the initial diagnosis
for surgery are called comorbidities and multi-morbidities [1]. In 2009, 49% of people
within Australia aged 65 to 74 had five or more long-term chronic health conditions and
this prevalence increased with age [23]. This means that patients presenting for THR
surgery are likely to have multi-morbidities. So the management of patient care for
patients with comorbidities needs to be addressed. This study clearly addresses the role
of comorbidities in patient recovery after THR surgery.
Firstly, in Chapter 2, we present a summary of the THR dataset that will be analysed.
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Data cleaning and missing data procedures are explained. We use the data summaries
to determine characteristics of THR patients. An understanding of the limitations of the
dataset prepare us for preliminary analysis. This analysis begins with linear regression,
explored in Chapter 3. We show that this type of model, one with only fixed effects, is not
appropriate in the context of our dataset as it does not address the correlation between
repeated measures within one patient. Therefore, this chapter provides motivation for
longitudinal data analysis, specifically mixed-effects modelling.
In Chapter 4 we present an introduction to mixed-effects modelling, subsequently using
the THR dataset, and a model selection process, to create an optimal model. We find
that variables such as age, gender and number of comorbidities significantly contribute to
a patient’s pain and function after surgery. We discuss methods of prediction relating to
mixed-effects models. For new patients that are not within the estimation model frame
the use of best linear unbiased predictions (BLUPs) of the random effects of patients with
similar characteristics is implemented.
For some THR patients a HHS measurement is taken at the point of surgery. This
means that the change in HHS after surgery can be determined. In Chapter 5, we continue
with mixed-effects modelling but the response variable is instead the change in HHS. The
predictor variables within this model vary significantly from the model in the previous
chapter. Through prediction we can assess whether a patient is likely to experience any
pain and function improvements at 24 months after surgery.
In Chapter 6 we introduce survival analysis using patient survival information, such
as date of death. We produce a Cox model to show that the number of comorbidities that
a patient suffers from is associated with their risk of survival [9]. The time-dependent
model is shown to be inappropriate for modelling the biomarker HHS as a predictor of
survival. This forms the motivation for joint modelling.
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In Chapter 7 we provide an overview of modelling both the survival and longitudinal
outcomes through joint modelling. We use this model framework to create a joint model
where survival status and HHS are both outcomes. We compare these results to the
optimal mixed-effects model in Chapter 4 as well as the HHS predictions. Specific patient
predictions, relating to both the HHS and survival outcome, are determined using dynamic
prediction.
Some THR patients undergo surgery on both their left and right hip. Often one side
is operated on first and then the second surgery is performed at a later time. In Chapter
8 we apply joint modelling where the survival outcome is second surgery. Therefore,
allowing us to assess the risk of a patient having to undergo a THR on their other side
after their initial surgery. This showed that patients who experience worse pain and less
function, after their first THR, are more likely to undergo a second surgery.
To address the problems associated with combining both pain and function, two im-
portant measures, into one score we then separated them into separate scores. These two
outcomes, pain score and function score, were then analysed independently. Joint mod-
elling with multivariate longitudinal outcomes was then introduced and applied within
the context of pain score and function score being separate longitudinal outcomes. Both
pain score and function score interacted differently with the survival sub-model showing
the importance of addressing two important measures separately.
In summary, this research explores THR surgery and develops statistical predictive
algorithms to determine the likelihood of recovery and satisfaction with surgery within
the first two years following surgery. Not only will this enable patients to make an
informed decision before choosing to undergo surgery but it will also lead to optimising
preoperative patient education as part of a greater holistic approach.
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Chapter 2
Data Summary
This thesis will analyse the clinical and health outcomes of data collected prospectively
for 3049 primary total hip replacement (THR) procedures between 1989 and 2013 at
the Royal Adelaide Hospital (RAH). The study will utilise data maintained as part of
the Orthopaedic and Traumas Joint Replacement Database, which includes data on pa-
tient socio-demographics, and death status cross-matched against the South Australian
Births, Deaths and Marriages Database. Clinical outcomes in the database include doctor-
assessed joint range of motion. Patient recorded outcomes include joint pain and function
measured at multiple points after surgery.
The dataset was in the form of a relational database (a database structured to recognise
the relations between stored data) and was subsequently converted to a flat file (removes
internal hierarchy) for the purposes of this study. Before analysing the dataset it was
important to identify erroneous data entries, so they could be removed and not affect
further analysis. Therefore, we spent time initially reformatting the data, addressing free
text fields and performing general data cleaning.
This Chapter will begin by explaining both the variables and the characteristics of
7
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the cleaned, and partially imputed, THR dataset that is used in later analysis. This is
done to provide clear context to the research problem. Following this, information about
the data cleaning procedures and imputation methods used will be explained. Therefore,
clarifying the decisions that were made when preparing the dataset for analysis. All data
analysis was completed using R [13].
2.1 The Data
The dataset received from the RAH contained information on THR patients with surgery
dates evenly spanned over a 25 year period, from the start of 1989 to the end of December
2013. We were given 92 variables, which included patient age, gender, lifestyle factors,
operation details, comorbidities, medications and longitudinal pain and function data
following surgery (see Appendix A.1 for a full description of the variables). The cleaned
dataset, which will be summarised in this section, is reduced to 2280 patients as a result
of data cleaning and missingness (see Sections 2.3 and 2.4). Table 2.1 shows descriptive
data, frequency and percentages of patient demographics, for THR patients. There are
more females than males, with 1341 (58.8%) females. Whether the operation is performed
on the left or right side is almost balanced with 450 (19.7%) patients who had both left
and right hip replacements. Figure 2.1 is a histogram of the age of THR patients at the
point of surgery. The solid black line marks the mean age of 67 years. The majority of
the patients (65%) were aged between 60-80 years old, at the time of THR surgery. The
youngest patient is 16 years old and the oldest is 100 years old.
Osteoarthritis (OA) is a disease that results in the degeneration of joint cartilage and
bone [1]. Rheumatoid Arthritis (RA) is a chronic disease that causes inflammation in
the joints resulting in deformity and immobility [1]. A high proportion of patients that









Figure 2.1: Histogram of the age of patients at the point of surgery. The black solid line
refers to the mean age of these patients, 67.2 years (n=2280).
present for THR suffer from either OA or RA. OA is the most common form of arthritis
that these patients suffer from when presenting for surgery, although this is not necessarily
the primary reason for surgery (see Table 2.1). Avascular Necrosis (AVN) is a disease
which occurs when a blood supply failure results in the death of bone tissue [1]. No
patients that presented for THR surgery suffered from both OA and RA. More patients
in the dataset suffer from AVN than RA but the majority of patients suffer from OA
(87.9%).
Many patients that present for THR surgery also suffer from comorbidities. Comor-
bidity is the presence of one or more additional diseases or disorders co-occurring with a
primary disease or disorder [1]. Approximately 70% of patients within the dataset have
comorbidities. Table 2.1 shows descriptive data on the ten most prevalent comorbidities
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Patient Demographics
n of patients 2280
Mean (SD) age (yrs) 67.2 (12.3)
Mean (SD) follow-up time (months) 36.8 (49.5)
Mean (SD) weight (kgs) 78.6 (17.7)








Osteoarthritis (n,%) 1734 (87.9)
AVN (n,%) 182 (9.2)





NIDDM1- stable 140 (6.1)




Current malignancy 38 (1.7)
Hypothyroidism 34 (1.5)





Four or more 94 (4.1)
Taking medication (n,%) 1829 (80.2)
1 Non-Insulin-Dependent Diabetes Mellitus.
2 Chronic Obstructive Airways Disease.
3 Congestive Cardiac Failure.
Table 2.1: Frequency (and percentages) of patient demographics for THR patients
(n=2280). Only the ten most prevalent comorbidities shown in table.
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in the dataset. The two most common comorbidities are hypertension (26%), abnormally
high blood pressure, and asthma (22%). The number of comorbidities that a patient
suffers from is also shown in Table 2.1. Approximately 33% of patients suffer from one
comorbidity, while only 22% suffer from two comorbidities. Due to these comorbidities,









Figure 2.2: Histogram of the weight of patients at the point of surgery. The x-axis is the
imputed weight measurement, which is the mean weight for each patient (n=1663).
The distribution of the imputed weight and height variables is also shown in Table
2.1. This application of imputation, due to missing data, is explained in Section 2.4. The
mean weight of patients is approximately 79 kg (sd=17.7kg) while the mean height is 165
cm (sd=12.1cm). Figure 2.2 is a histogram of weight where the x-axis is the imputed
weight variable, which is the mean weight for each patient. There is a right skew in the
histogram as there are some patients with heavier weights, while the majority of patients
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(64%) weigh between 60-90 kg.
The dataset contained the date of death (DOD) for approximately half of the patients
(47%). This information is useful for examining whether there is a relationship between
operation date and death when considering other factors such as patient age, gender, op-
eration details and comorbidities. This is explored through survival analysis (see Chapter
6). Half of the patients with DOD’s die within 8 years following their operation date.
This may be due to hospital records losing track of patient information, such as their
DOD, after long periods of time. Therefore, those patients that die within eight years
are recorded whereas those that die well after this time are not recorded due to loss of
contact, creating a bias in the data.
Figure 2.3: Diagram of Acetabulum and Femoral implants used for THR surgery [2].
In THR surgery a patient receives an acetabulum and a femoral implant. These im-
plants are artificial prothesis that replace the ball and socket bones in the hip joint.
Figure 2.3 shows the components of the acetabulum and femoral implants and their po-
sition within the hip following surgery. There are different brands associated with each
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implant and the prevalence of each brand for both the acetabulum and the femoral are
shown in Table 2.2. There are specific combinations of acetabulum and femoral implants
that are used, such as Exeter and Exeter for the acetabulum and femoral implant re-
spectively. Only the most common implant combinations are shown in Table 2.2. We
see that Trilogy and CPT is the most common type of acetabulum and femoral implant
combination, as 44% of patients use this.
Type of Implant Number of Patients (%)
(Acetabulum & Femoral) n = 2280
Trilogy & CPT 1004 (44.0)
Exeter & Exeter 346 (15.2)
Vitalock & Exeter 215 (9.4)
Charnley & Charnely 182 (8.0)
PCA & PCA 108 (4.7)
Table 2.2: Table of the types of Acetabulum and Femoral Implants (n=2280).
After surgery, prosthetic hips can sometimes wear out or cause other problems and a
further operation is required to replace the implant. This is called a revision. As expected
the survival of the acetabulum and femoral are almost identically distributed. This is be-
cause most procedures replace both the acetabulum and femoral implants simultaneously.
Though revision is often used as a measure of success after THR, where lack of need for
a revision is a positive outcome, we can also look at the pain and function of a patient
as indicative of the benefits of the surgery. To measure the pain and function following
THR we can use the HHS.
2.2 Harris Hip Score
The Harris hip score (HHS) is a clinician-based outcome tool used to evaluate patient
recovery following THR surgery [12]. It is a score between 0 and 100, where higher scores
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are associated with less pain and better function and lower scores are associated with more
pain and reduced function. A HHS of less than 70 is classified as poor pain and function
[12]. Figure 2.4 shows a histogram of the HHS for all patient follow-up measurements. It
is clear that this variable is bounded at 100 and is left skewed. The majority of patients










Figure 2.4: Histogram of the Harris hip score of patients at each follow-up (n=1905).
Following surgery each patient completes an outpatient form at each follow-up visit.
The outpatient forms contain a series of questions relating to the mobility and pain of
their joint(s). For example, the data contains the range of motion in internal and external
rotation of the hip, if there is a limp and what causes it, leg length and leg power. These
fields are then used to calculate the Harris hip score (see Appendix A.2 for full description
of the HHS calculation process). It is intended that each patient completes this outpatient
form at 3, 12 and 24 months after surgery, depending on the precise timing of their return
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clinic visits. The time between the date of surgery and the date of an outpatient form
being completed is called the ‘follow-up time’.
Figure 2.5: Distribution of the HHS for non-negative and non-zero follow-up times.
Follow-up times greater than 26 months are excluded. Points labelled blue show the
HHS measurements at the time of surgery (follow-up time is zero). The coloured lines
display the density of the points where red indicates high density and green indicates low
density (n=1905).
Figure 2.5 shows the distribution of the HHS for non-negative and non-zero follow-up
times, where follow-up times greater than 26 months are excluded. The x-axis is the
follow-up time in months and the y-axis is the HHS. Points labelled blue show the HHS
measurements at the time of surgery (follow-up time is zero). The coloured lines display
the density of the points where red indicates high density and green indicates low density.
It is clear that over time, the follow-up data becomes more sparse. Nevertheless, we see
that the 3, 12 and 24 month scheduled follow-up times are directly reflected in the data.
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Table 2.3 shows the follow-up distribution of THR patients for the first six follow-
ups. We see that 84% of patients have a minimum of at least one assessment during the
postoperative period with 64%, 41% and 26% assessed 2, 3 and 4 times respectively. Some
patients have as many as 10 follow-up assessments with the maximum being a patient
with 14 follow-up assessments. Almost 50% of the patients within the dataset have at
least three follow-up measurements, which encourages the exploration of a quadratic term
for time (months) in later models.
Follow-up Number of patients (%) Mean (months), (SD)
First follow-up 1905 (83.6) 5.7, (16.6)
Second follow-up 1464 (64.2) 12.3, (20.1)
Third follow-up 942 (41.3) 27.2, (27.6)
Fourth follow-up 588 (25.8) 50.0, (34.7)
Fifth follow-up 338 (14.8) 71.6, (40.3)
Sixth follow-up 175 (7.7) 94.2, (45.0)
Table 2.3: Table of the follow-up distribution of THR patients for the first six follow-ups
(n=1905).
The HHSs given within the data were used primarily throughout analysis as the lon-
gitudinal outcome. However, there are obvious issues with combining two important
measures such as pain and function into a single variable. In Chapter 8 we will address
this explicitly by developing an algorithm which can decompose HHS into its pain and
function components for use, separately in a multivariate longitudinal model.
At this stage, with a greater understanding of the THR dataset, we can now explain
the process that was used to clean this dataset. Understanding this process is important
as it makes clear the limitations of this dataset and the decisions that were made to
address these limitations.
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2.3 Data Cleaning
Data cleaning is the process of detecting inaccurate records from a dataset and then
determining whether to modify or delete these entries. For example, a patient that was
entered as 6 years of age is not a real measurement as patients this age do not undergo
THR surgery at the RAH. In this case you could either check the patient records and
correct the age, or if that information is not available, remove the age or the entire
patient from the dataset. In our case, we did not have access to records that would enable
us to correct inaccurate details, so the following decisions were made.
• The patient that was 6 years of age was removed.
• The weight of patients was recorded in kilograms, therefore entries that were greater
than 200kg or less than 30kg were removed.
• Heights that were entered as greater than 210cm or less than 60cm were removed.
We also decided to remove the four patients from the dataset who had undergone a
THR on both sides within one operation, a bilateral THR. These specific patients were
removed due to the potential difference in recovery from undergoing a bilateral THR
compared to a regular THR.
Another facet of data cleaning is simplifying and relabelling variables. Variables may
not be inaccurate but may be in an inappropriate form. An example of which in our
data was the year of operation being entered inconsistently. The year of operation was
sometimes entered as two digits, such as 93, but needed to be converted to four digits,
1993.
New variables were also created using natural language processing, which is the ap-
plication of computational techniques to the analysis of natural language. For example,
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within the dataset there was a variable that specified patient medications. The informa-
tion was entered in the following form for five patients:
[1] Aspirin, Voltaren, Frusemide, Provastatin...
[2] Aspirin, Warfarin, Tramadol, Ibuprofen
[3] ATROBEL,CALTRATE
[4] Aspirin, Zimsta, Coversyl, Simvastatin...
[5] ATRVNT, VNTLN, BEDOFORTE, ARUDIS, LASIX...
We created a variable that identified if a patient was taking a strong opioid by using
natural language processing to mark when the words morphine, tramadol, endone and
others were mentioned. Therefore, the second patient in the above list would be iden-
tified as using strong opioid medication due to the mention of tramadol. This was also
completed for other medication groups such as paracetamol and weak opioids. Whether a
patient smoked marijuana was also determined using this method on a social drug spec-
ification variable. Variables such as the hip side, implant brand and place of residence
were converted to numeric factors.
The dataset specified separately whether a patient smoked and how many cigarettes
a day they would have. These two variables were combined to create one variable that
identified patients as either non-smokers, light smokers or heavy smokers. When rela-
belling this variable we made the assumption that a patient with an unspecified number
of cigarettes per day, but that is specified as being a smoker, is a light smoker. A similar
process was completed for the relabelling of the alcohol status variable. These variable
relabelings are outlined in Appendix A.3.
Another new variable was created to combine patient information about comorbidities.
The dataset contained a binary variable that identified whether a patient suffered from
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a comorbidity and also a variable that stated the specific comorbidity, number coded
from 1 to 45, where 14 is ‘other’. For example, one patient is listed as suffering from
stable insulin-dependent diabetes mellitus, prostatism, asthma, hypertension and ‘other’.
Using this information we created a new variable, with an upper limit of ‘four or more’,
which stated the number of comorbidities a patient suffers from at their first follow-up.
Therefore, the above patient was marked as suffering from four or more comorbidities.
After detecting and addressing inaccurate records from the dataset the next step was
to develop protocols for dealing with missing data.
2.4 Missing Data
Often observations within electronic health records are not complete. For example, a
patient may have their age recorded but not their place of residence. This empty field is
called missingness or missing data. There are different ways that we can view missingness
that affect how we address entries not being observed. For example, a patient may not
have their height or weight measured at the time of surgery. Therefore, we can view this
missingness as underlying values that could have been observed but were not, potentially
due to the patient’s request or lack of time. We do not question whether a patient has
a height or weight just that it was not measured. Therefore, it is more natural to treat
these unobserved values as missing [19]. Likewise for variables such as place of residence
we do not assume that a patient has no place of residence even if this is unobserved.
In other cases it may not be as clear. If a patient has no entry in relation to the
type of medication that they take, does this imply that a patient is not on medication
or that this entry is missing? In this research, following consultation with the RAH, it
is assumed that missing entries for patient medication are far more likely to imply that
20 Chapter 2. Data Summary
a patient does not take that form of medication. We also assume that patients with no
comorbidity information do not suffer from comorbidities. The variable which recorded a
patient’s previous surgery contained a large amount of missing data due to the inherent
difficulty in accessing that information. We therefore excluded the entire variable from
our analysis.
Some variables, such as the Harris hip score, were imperative to our analysis. Using
some sort of numerical imputation of these missing values was not deemed appropriate
due to the vital contribution they brought to the analysis. Patient observations that had
missing values in this variable, or with missing follow-up times, were therefore excluded
from the analysis. The effect that this had on the number of patients is shown in Figure
2.6, which is a flow chart of the effect of missingness on the number of patients within
the dataset. This reduced the dataset to 1905 patients. For variables such as smoker and
alcohol status we also did not assume that an unobserved value means that a patient does
not smoke or drink. As a result missing entries in the variables smoker and alcohol status
were replaced with NA but were still included in the analysis.
2.4.1 Imputation
Imputation is the process of filling in missing values and then using the resultant completed
data for analysis [19]. When considering imputation of some of the missingness within
the dataset there were some important considerations. We should consider the intended
use of the model, which in this case is the prediction of a patient’s pain and function after
surgery. Previous research has shown that weight and height are all important predictors
in the context of THR surgery [4, 16, 8]. For this reason, the missing values in these
variables were addressed using imputation techniques that are outlined in this section.












remove patient with age=6 and bilateral patients
remove follow-up times ≤ 0
remove NA follow-up times
remove NA HHSs
Figure 2.6: Flow chart of the effect of missingness on the number of patients to be
analysed.
For weight and height, it was assumed that the missingness is completely random.
We acknowledge that variables with lots of missing data points would be expected to
end up with larger error terms than those with fewer missing data points, so the ability
to detect significant relations to those variables would be limited accordingly. For these
reasons we did the following exploration to decide whether the missingness within the
weight and height variables should be addressed using imputation or not. Specifically
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mean imputation, where means from subgroups of the sample are substituted [19]. In
this case, we explore substituting in means at a patient level.
Figure 2.7 shows the missingness in the covariates weight, height, implant brand, place
of residence, smoker level and alcohol level. The histogram in Figure 2.7 displays the
proportion of missing data within each of the covariates. The variables height and weight
contain the most missingness with approximately 70% of observations being unobserved.
The plot on the right, in Figure 2.7, shows the most frequent combinations of missingness
across the covariates. We see that approximately 32% of observations within the dataset
do not have a measured weight, height, alcohol or smoker status and place of residence.
The covariates age, gender, OA, RA, AVN, specific medications and comorbidities are not
included due to their lack of missingness. Other variables that are not included here are
not considered as important, such as date of previous surgery.
Since weight and height are potentially important variables, as discussed above, we
need to address their high missingness. We decided to calculate the mean weight of each
patient and use mean imputation to address the missingness. Though there are some
patients that have significant weight loss or gain the majority of patients lie between a
weight of 50-100 kg and maintain a fairly fixed weight throughout the follow-up period.
The change in height over time is slightly negative for some patients but overall fairly
insignificant and approximately constant.
Figure 2.8 shows a comparison between the distribution of the response variable, HHS,
for missing and non-missing covariates. Where the x-axis outlines the type of covariate
and the y-axis is the HHS. This shows that the distribution of HHS does not appear to be
dependent on missingness, including missingness in weight and height. Similarly the age
and gender distributions are approximately the same across the missingness in weight and
height. Within this context using the mean of previous weight and height measurements




















































































































Figure 2.7: Missingness in the covariates weight, height, implant brand, place of residence,
smoker level and alcohol level. Left: Histogram displaying the proportion of missing data
within each of the covariates. Right: Plot showing the most frequent combinations of
missingness across the covariates; e.g. approximately 32% of observations within the
dataset do not have a measured weight, height, alcohol or smoker status and place of
residence (n=1905).
to impute missing observations is appropriate.
Since weight is a variable that is calculated at each follow-up we impute the mean
weight of each patient for each follow-up. If a patient has three follow-ups and their weight
is unobserved for their final follow-up, then all weight measurements for that patient are
the mean of their previously observed weights. A similar method is used for the variable
height. This lowers the missingness as there are 1290 patients (57% of patients) that have
at least one weight measurement with a corresponding valid HHS and 69% have at least
one observed weight with or without a corresponding valid HHS. Therefore, we impute
the mean weights and heights before removing the missingness in the HHS so as to avoid
losing information relating to a patient’s weight and height. This decision helped us retain
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Figure 2.8: Comparison of the distribution of Harris hip score for missing and non-missing
covariates weight, height, implant brand, place of residence, smoker level and alcohol level
(n=1905).
and effectively use patient weight and height information.
This chapter displayed the importance of data cleaning and addressing missing data
before proceeding to analysis. Specifically using mean imputation for the weight and
height variables. We note that multiple imputation was not used and further work into
this method would be valuable. Summaries of the cleaned data, described earlier in this
chapter, show the demographic of THR patients, such as age and gender. Now that we
understand the nature of the data and have addressed the missingness and erroneous data
entries we can approach longitudinal data analysis to predict patient postoperative pain
and function based on preoperative factors.
Chapter 3
Linear Modelling
The first statistical method that we used to explore the total hip replacement (THR)
dataset was linear modelling. Therefore, in this chapter we fit a linear model with in-
dependent, homoscedastic residual errors where Harris hip score (HHS) is the response
variable. However, before we explore linear modelling we present the bivariate analyses of
the THR dataset as these results form the basis of feature selection for the linear model
in this chapter. Therefore, this chapter begins with a summary of the bivariate analysis
and is followed by an exploration of linear modelling.
In view of the structure of this dataset, and of the results shown in the bivariate
analysis presented at the start of this chapter, the assumptions of independence and
homoscedasticity of the HHS measurements are not appropriate. Therefore, this chapter
provides the motivation for mixed-effects modelling used in Chapter 4. Nevertheless, the
linear modelling results are still outlined below as an important part of the analysis that
follows.
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Figure 3.1: Plot of the Harris hip score at each follow-up time for all patients. The points
mark each observation and each line connects the observations between one patients. The
follow-up times are restricted to 48 months (n=1720).
In this section, we present the bivariate analyses of the THR dataset. These results
are the basis of feature selection for the linear model in this chapter, and mixed-effects
models in Chapter 4.
Since we are interested in the HHS of patients over time we begin by examining the
relationship between these variables, follow-up time and HHS. Figure 3.1 displays the HHS
on the y-axis and the follow-up time on the x-axis, for all patients. The points mark each
observation and each line connects observations between one patient. Points that are not
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connected to lines represent patients with only one HHS observation. The follow-up times
are restricted to 48 months. It is clear that there is great deviation between patient HHS
trajectories. While some patients appear to have a fairly constant HHS, other patients
are extremely variable. It is also clear that the time at which follow-up’s occur is variable,
especially for follow-up times greater than 24 months.
We can likewise explore the relationship between other explanatory variables and HHS.
Out of the large number of variables within this dataset a subset of variables was selected,
to explore through analysis. This was done with the help of clinicians. These variables
were age, gender, follow-up time, side of hip operated on, mean weight, mean height,
implant brand, osteoarthritis status, rheumatoid arthritis status, AVN status, place of
residence, specific medications, number of comorbidities, smoker status and alcohol status.
These were selected as they were of particular interest to the clinicians but also due to
practical reasons, such as low missingness.
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Figure 3.2: Plot of the Harris hip score at each follow-up time for five selected male and
female patients. Follow-up times are restricted to 48 months (n=10).
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We are interested in the effect of these preoperative factors on HHS over time. Thus
in Figure 3.2 we plot HHS against follow-up time for several selected patients from both
genders. From this figure we see that in general, HHS tends to slightly decrease with
time after 12-24 months. Some patients display a linear change in HHS over time but
there are also patients for whom individual profiles strongly deviate from a linear trend.
HHS measurements adjacent in time are fairly well correlated. The HHS measured at
the patient’s first follow-up appears to, at least partly, determine the overall level of the















Figure 3.3: Side-by-side boxplot of the Harris hip score for each age strata (n=1720).
We can also investigate the medians and spread of HHS measurements for different
variables through boxplots. Figure 3.3 presents a side-by-side boxplot of the HHS of
patients within different age bands. We see that patients who are older than 80 years
have a lower median HHS. Patients associated with the highest median HHS are aged
between 40 to 70 years old. As there are less patients within the dataset who are older
than 80 years old, a possible explanation could be that patients only underwent surgery at
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this age if their pain and function was particularly poor. We note that a disadvantage of
this plot, and all boxplots within this section, is that they do not reflect the longitudinal
structure of the dataset. Nevertheless, they can still provide valuable insight into the















Figure 3.4: Side-by-side boxplot of the Harris hip score for each weight strata (n=1720).
Figure 3.4 shows a side-by-side boxplot of HHS measurements separated by patient
weight. Patients with weights heavier than 100kg have a slightly lower median HHS.
Likewise, patients with weights lower than 50kg also have a lower median HHS. This
supports the clinicians’ assessment that the heaviest patients are often associated with
poor pain and function recovery after surgery. Overall, there does not appear to be a
significant difference between the distributions of HHS for the weight strata between 50kg
and 100kg, which all have an approximate median HHS of 80.
Avascular necrosis (AVN), also called osteonecrosis or bone infarction, is death of bone
tissue due to interruption of the blood supply [1]. Figure 3.5 shows side-by-side boxplots
of the HHS for patients with and without AVN, where 1 indicates the patient does not
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Figure 3.5: Side-by-side boxplot of the Harris hip score for patients with and without
AVN, where 1 indicates the patient does not suffer from AVN and 2 indicates the patient
does suffer from AVN. Left: patients who are female. Right: patients who are male
(n=1720).
suffer from AVN and 2 indicates the patient does suffer from AVN. The left plot is of
female patients and the right plot is of male patients. Within this dataset, patients with
AVN appear to have a lower HHS than patients who do not suffer from AVN. This is true
across both male and female patients. Interestingly, female patients who do not suffer
from AVN have a similar median HHS to male patients who do suffer from AVN. This
suggests that males are associated with a higher HHS overall, supported by Figure 3.2. To
check this possibility, we look at the overall mean of HHSs for each gender. It shows that
males have a mean HHS of 77.6 (sd = 17.2) while females have a mean HHS of 73.7 (sd
= 18.1), where the p-value for the t-test comparing male and female HHSs is < 0.0001.
This further confirms that males are associated with a higher HHS.
The number of comorbidities that a patient suffers from is of particular interest within
this study. It is hypothesised that suffering from more comorbidities is associated with a
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Figure 3.6: Side-by-side boxplot of the Harris hip score for patients with a differing number
of comorbidities. Left: patients who are female. Right: patients who are male (n=1720).
lower HHS. Figure 3.6 compares the distribution of HHS with the number of comorbidities
that a patient suffers from. The left plot is of female patients and the right plot is of male
patients. The side-by-side boxplot of HHS for females shows a consistent decrease in the
median HHS as the number of comorbidities increases. This supports the hypothesis that
suffering from less comorbidities increases your association with good pain and function
recovery after THR surgery. In contrast, the boxplots of HHS for male patients shows a
less consistent, but still slight, decrease in HHS as the number of comorbidities increases.
An exception to this is the median HHS for males with one comorbidity, which is greater
than the median HHS for male patients with no comorbidities. Overall, Figure 3.6 shows
that, particularly for females, there is a potential relationship between the number of
comorbidities that a patient suffers from and their HHS after surgery. For males this
relationship is less distinct.
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Figure 3.7: Side-by-side boxplot of the Harris hip score for patients separated by their
place of residence: 1 indicates the patient lives at home alone and is independent, 2
indicates they live at home alone and with external support, 3 indicates they live at home
with others and are independent, 4 indicates they live at home with others and with
support and 5 indicates they live in another situation. Left: patients who are female.
Right: patients who are male (n=1720).
Figure 3.7 shows a side-by-side boxplot of HHS measurements separated by a patient’s
place of residence. Within this variable, 1 indicates the patient lives at home alone and is
independent, 2 indicates they live at home alone and with external support, 3 indicates
they live at home with others and are independent, 4 indicates they live at home with
others and with support and 5 indicates they live in another situation (e.g. nursing home).
The left plot is of female patients and the right plot is of male patients. It is clear that
patients who require external support (levels 2 and 4) have lower median HHSs. Likewise
patients whose place of residence is recorded as ‘other’, such as nursing homes, are also
associated with lower median HHSs for both males and females. Again, females appear
to have a lower HHS than males across each different option for place of residence.
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The results of this bivariate analysis identify some of the variables that may be predic-
tive of HHS after surgery, such as age, gender and number of comorbidities that a patient
suffers from. Therefore, using the variables identified in this section, we can now build
models that predict HHS.
3.2 Linear Modelling
Linear models allow us to describe a continuous response variable, in this case the HHS,
as a function of predictor variables. This description can then help us make pain and
function predictions for THR patients. Firstly, we fit a linear model with independent,
homoscedastic residual errors to the HHS from the THR dataset. In view of the structure
of this data, and of the results shown in the exploratory analysis presented earlier in this
chapter, the assumptions of independence and homoscedasticity of the HHS measurements
are not appropriate. The structure of the data will be properly taken into account,
using more advanced linear models, in Chapter 4. Nevertheless, the results of this linear
modelling are still outlined below as an important part of the analysis that follows.
Linear, or fixed effects, models make inferences about the population from which the
subjects of the dataset are drawn, in this case the patients. However, these models do
not account for the correlation within patient measurements. The linear model can be
written as:
Ri = Xiβ + εi,
εi ∼ N(0,σI),
(3.1)
where Ri is the vector of observed HHSs for patient i, β is the fixed-effects parameters
for the covariates used in constructing the design matrix Xi, and εi are independent,
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normally distributed error terms. Therefore, we consider the following model for HHS:
HHSij =β0 + β1Sexi + β2Agei + β3FollowupTimeij + β4FollowupTime
2
ij+
β5Sidei + β6Weighti + β7Heighti + β8ImplantBrandi+




β18SmokerStatusi + β19AlcoholStatusi + εij.
(3.2)
In the model specified in Equation 3.2, HHSij is the value of HHS measured for patient
i at observation number j. In the explanatory (fixed) part of the model, Sexi is gender,
Agei is the age of patient i at the point of surgery, FollowupTimeij is the follow-up time for
observation j, Sidei is the operation side, Weighti is the mean weight for patient i, Heighti
is the mean height for patient i, ImplantBrandi is the implant brand, Osteoarthritisi
is baseline osteoarthritis status, RheumatoidArthritisi is baseline rheumatoid arthritis
status, AVNi is baseline AVN status, PlaceOfResidencei is place of residence at point of
surgery, NumberOfComorbsi is the baseline value of the number of comorbidities patient
i suffers from, SmokerStatusi is the baseline smoker status and AlcoholStatusi is the
baseline alcohol status. We note that Paracetamolij, NSAIDSNonselectCoxInhibitorij,
OpioidStrongij and NSAIDSCox2Inhibitorij are the status of specific medications that
are defined in Appendix A.3. The βk, where k = 1, . . . , 19, are the variable specific
effects, with β0 denoting the intercept.
The variables Sex, Side, ImplantBrand, Osteoarthritis, RheumatoidArthritis, AVN,
PlaceOfResidence, Paracetamol, NSAIDSNonselectCoxInhibitor, NSAIDSCox2Inhibitor
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and OpioidStrong are all nominal categorical variables. All of these nominal categorical
variables have two levels except for ImplantBrand, which has three levels, and Place-
OfResidence, which has five. SmokerStatus, AlcoholStatus, NumberOfComorbs are ordi-
nal categorical variables with three, three and five levels respectively. Age, FollowupTime,
Weight and Height are all continuous quantitative variables.
The random part of the model shown in Equation 3.2 is the residual random error,
εij. We assume that errors for each observation are independent and normally distributed
with mean 0 and constant variance σ2. Obviously these assumptions are not correct due
to the longitudinal structure of the dataset. Thus, this analysis is only an illustration of
the nature of the dataset.
To further simplify the model shown in Equation 3.2 we test the hypothesis of whether
there is an effect for each variable using analysis of variance with a backward algorithm
and an F -test p-value as the heuristic. This performs F -tests for continuous covariates and
groups of contrasts for factor variables included in the model. Using a step-wise process
we remove the least significant variable until the p-value of the F -test for each variable
within the model is statistically significant at the 5% level. The resulting simplified model
determined through this step-wise process is shown in Equation 3.3.
HHSij =β0 + β1Sexi + β2Agei + β3FollowupTimeij + β4FollowupTime
2
ij+
β5Weighti + β6Osteoarthritisi + β7AVNi + β8PlaceOfResidencei+
β9OpioidStrongi + β10NumberOfComorbsi + β11SmokerStatusi+
β12AlcoholStatusi + εij.
(3.3)
Each nominal categorical and ordinal categorical variable within the model has a
reference level that we need to acknowledge to make appropriate inferences about the
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estimated coefficients. The reference level for the variables Osteoarthritis and AVN is
not suffering from these diseases. The reference level for OpioidStrong, SmokerStatus
and AlcoholStatus is not taking any opioids, not smoking and not drinking, respectively.
The reference level for Gender is female, for PlaceOfResidence is independent and home
alone and for NumberOfComorbs is suffering from no comorbidities. This means that, for
example, the coefficient for Gender, β1, indicates the mean difference of the HHS between
males and females, adjusted for all other covariates in the model. This is detailed in
Appendix A.1 and A.3.
Table 3.1 shows the parameters estimates for the optimal model shown in Equation
3.3. The positive estimates for the coefficients indicate a favourable effect on HHS. For
example, being male is associated with a higher, and therefore better, HHS, adjusted on
the other covariates (we note that each covariate effect has to be interpreted as being
adjusted on the other covariates, though this is not always stated). In contrast, the
negative estimated coefficient relating to the number of comorbidities a patient suffers
from, indicates a worse HHS for patients with a large number of comorbidities. However,
as was discussed earlier, the model does not take into account the correlations within
patient observations. Thus it should not be used as a basis for inference.
The misspecification of this model is reflected in Figure 3.8, which is a side-by-side
boxplot of the studentized residuals for ten randomly selected patients. A studentized
residual is the residual divided by an estimated of its standard deviation. The boxplots
of the residuals for the model (Equation 3.2) illustrates the basic problem with ignoring
the correlation within patients measurements. These correlations are incorporated into
the residuals, as there is heterogeneity in the residuals. This leads to an inflated estimate
of the within patient variability [11].
We also discovered through this process that the response variable, HHS, requires a
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Parameter Estimate SE p-value
Fixed Effect Intercept (mean change in 84.97 3.75 <.0005
Estimates HHS at 0 months)
Slope (months after surgery) 1.03 0.12 <.0005
Quadratic (months)2 -0.02 0.003 <.0005
Sex (if male) 5.23 0.88 <.0005
Age (yrs) -0.16 0.04 <.0005
Weight (kgs) -0.10 0.02 <.0005
AVN -4.39 1.78 0.01
OA 4.06 1.22 0.0009
Number of Comorbidities (zero)
One 0.40 1.15 0.72
Two -2.59 1.22 0.03
Three -4.08 1.39 0.003
Four or more -7.20 3.89 <.0005
Place of Residence (home alone & indep)
Home alone & external support -4.44 1.68 0.008
Home with others & independent -1.00 0.99 0.31
Home with others & support -7.40 1.25 <.0005
Other -7.80 2.82 0.005
Smoker (non-smoker)
Moderate -5.19 1.39 <.0005
Heavy 3.63 3.53 0.30
Alcohol (non-drinker)
Moderate 1.77 0.82 0.03
Heavy 4.83 3.93 0.22
σ 16.52
Table 3.1: Model parameters for linear model HHS (Equation 3.3); Number of observa-
tions: 1905. Number of patients: 744.
transformation to better address the assumptions of linear models. HHS is a variable
that is bounded between 0 and 100, shown in Figure 2.4 in Chapter 2. To account
for this bounding we applied multiple transformations to the variable HHS (e.g. a log
transformation, which did not work). The logit transformation was chosen as the most
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Figure 3.8: Side-by-side boxplot of the studentized residuals for ten randomly selected
patients (n=10).
appropriate transformation as it increased the normality of the residuals and converted
the HHS to lie between −∞ and ∞ instead of 0 and 100. The logit transformation is
outlined in Equation 3.4. We added a 0.1 offset to account for HHS measurements that
are 100. This offset stops these observations from being undefined under transformation.
logitHHS = log
 HHS + 0.1
100.1−HHS
 (3.4)
Figure 3.9 displays a histogram of the transformed HHS measurements, using the logit
transformation (Equation 3.4). We see that the transformed HHS measurements that are
approximately 6.9 are outliers in this histogram, while the rest of the measurements are
fairly normally distributed. These measurements of 6.9 correspond to a HHS measurement
of exactly 100. Therefore, we see poor behaviour from HHS measurements of 100, which
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Figure 3.9: Histogram of the transformed Harris hip score of patients at each follow-up.
The transformation used is the logit transformation outlined in Equation 3.4 (n=1720).
is a problem that will be explored in further analysis. Nevertheless, this transformation
does significantly improve the behaviour of the residuals to fit the assumptions of the
linear model. Therefore, it will be applied in further analysis.
Now that we have a greater understanding of the relationship between predictor vari-
ables and the HHS, as well as an appropriate transformation for the response variable,
we progress beyond a linear model to a mixed-effects model. A model, that in contrast,
appropriately takes into account the repeated measures structure of the dataset.
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Chapter 4
Mixed-Effects Modelling
An alternative approach to the modelling of the total hip replacement (THR) dataset,
which accounts for the correlation between the observations, is to use linear mixed-effects
models. This method will be defined and explored in this chapter. Using this approach,
the hierarchical structure of the data is addressed through the inclusion of random effects.
These random effects describe the contribution of the variability at different levels of the
hierarchy within the dataset. For example, random effects can describe the contribution
of the Harris hip score (HHS) variability at an individual patient level as well as total
variability across all patients.
In this chapter we begin by considering a random intercept model and a random
intercept and slope model. We also address the use of restricted maximum likelihood
(REML) or maximum likelihood (ML) estimation. A summary of the analyses is then
provided. Following this, methods of HHS prediction are explored to help determine which
prediction methods are optimal depending on the amount of patient information that is
available.
The linear mixed-effects model is such that it combines both random and fixed effects.
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It can be written as,
Ri = Xiβ + Zibi + εi,
bi ∼ N(0,D),
εi ∼ N(0,Σi),
b1, . . . ,bN, ε1, . . . , εN are independent,
(4.1)
where Ri is the vector of continuous responses, Xiβ is the fixed component and Zibi is
the random component, where i denotes the subject, in this case the patient. The vector
of the residual errors for patient i is εi. There is no index for the vector of parameters β
as it is the same for all patients. It is the fixed-effects parameters for the covariates used
in constructing the design matrix Xi. Similarly Zi and bi are the matrix of covariates






































This representation, shown in Equation 4.1, is in the general form. A more specific
form of this model could be the random intercept mixed-effects model. Where i is the
subject number, ni is the number of observations for that subject, j is the number of
explanatory variables included and Ri1 is the HHS for the i-th patient’s first follow-up.
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where age is not time dependent, as it is the baseline age, and time refers to the
follow-up time of each HHS observation. The βj are the variable specific effects, with
α denoting the fixed component of the intercept. The random part of the model is the
residual random error, εij and the random intercept, bi. We assume that both the random
intercepts and the residual random errors are independent and normally distributed, as
discussed with Equation 4.1. We note that even though the within patient form of the
model appears aliased, across all patients this is not the case. Therefore, using this model
the i-th patient’s first follow-up can be written as,
Ri1 = α + β1agei + . . .+ βjtimei1 + bi + εi1,
where α + bi is the random intercept, while the slopes remain fixed. This random in-
tercept model effectively incorporates correlations between observations for each patient.
Let’s suppose there is a relationship between HHS and follow-up time which is different
for each patient. This is when we can include not only random intercepts but also ran-
dom slopes. In a random slopes and intercepts model both the intercept and the slope
have random components for each patient. Or more specifically, the individual random
intercept and slope capture the individual deviations from the mean baseline value and
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where time, representing follow-up time, is now included in the random effects design
matrix. Therefore, using this model the i-th patient’s first follow-up can be written as,
Ri1 = α + β1agei + . . .+ βjtimei1 + bi0 + bi1timei1 + εi1,
where the random intercept is α + bi0. The coefficient of the i-th patient’s follow-up
time is βj+bi1, which includes the random slope bi1. We note that correlation between the
random intercept and slope will be allowed. The only explanatory variable that will be
modelled as potentially having a random coefficient will be the follow-up time associated
with patient observations. This is because it is feasible that there is a relationship between
HHS and follow-up time that is different for each patient. In Chapter 8 we will also
consider the mixed-effects models outlined above, where the response variable Rij is the
pain or function score, instead of the HHS.
Common heuristics used for mixed-effects models are Akaike Information Criteria
(AIC) and Bayesian Information Criteria (BIC). These two terms are a function of the
likelihood value (a measure of fit) and the number of parameters in the model (a measure
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of complexity). The AIC and BIC are defined as,
AIC = −2× L(θ) + 2× p,
BIC = −2× L(θ) + 2× p× lnn∗,
(4.2)
where L is the likelihood and p is the number of parameters in θ, where θ denotes the
unknown parameters. Depending on what method we use to perform maximum likelihood
estimation we obtain different AIC and BIC calculations. For ML we let n∗ = n and for
REML, n∗ = n− p [33].
REML and ML are two functions that can be used to perform maximum likelihood
estimation. The limitation of ML is that the estimator for the variance is biased by a
factor of (n− p)/2, for p explanatory variables [33]. This is because ML ignores the fact
that within mixed-effects models we also estimate the intercept and the slope. REML
is used due to its ability to correct the estimator for the variance. The log-likelihood






i × V −1i ×Xi|−0.5 × LML(θ), (4.3)
where Xi is the design matrix for the fixed effects, Vi is the variance of the normally
distributed responses and LML(θ) is the log-likelihood function for ML. Though these
two estimators often give similar results they do differ substantially [10]. As we see
from Equation 4.2 and 4.3 an AIC calculated using REML is not comparable to an AIC
calculated using ML and likewise for BIC. This means that at different stages in the
model selection process REML and ML will be applied to determine the optimal fixed
and random structure.
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4.1 Model Selection
In earlier sections we discussed that although the original dataset contained many vari-
ables this was narrowed to 18 explanatory variables, with the aid of the clinicians as shown
in Chapter 3. The strategy used for model selection is the top-down strategy [33] and is
as follows:
• Begin with a model that contains all explanatory variables. A quadratic term for
the variable follow-up time is included, as mentioned in Chapter 2. Due to the large
number of explanatory variables no interactions are included.
• Using this model, determine the optimal random components structure. This de-
creases the risk of the random components having any information that we want
in the fixed components part of the model. Since ML cannot be used to compare
two models with nested random structures, as the variable estimators are biased,
we must use REML estimators. In this step the REML likelihood ratio test, AIC
and BIC are used to determine the optimal random components structure, whether
to include random intercepts and slopes.
• After determining the optimal random structure we find the optimal fixed structure.
To compare models with nested fixed effects and the same random structure, ML
estimation must be used. Both the F -statistics and the t-statistics can be used to
compare models with differing fixed structures. The least significant variables are
removed until all fixed effects are significant at the 5% level.
• Now that we have obtained the optimal random effects and fixed effects structure
we have the final model. Lastly, the final mixed-effects model is calculated using
REML estimation.
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Using this strategy a full model, included all explanatory variables, was fitted. To
compare random effects structures a random intercept, random slope and intercept and
generalised least squares model were compared. The models were estimated with REML
to allow the likelihood ratio test to be applied to help compare the models. The random
intercept model is written as,
logit(HHS)ij =α + β1Sexi + β2Agei + β3FollowupTimeij + β4 × FollowupTime2ij+
β5Sidei + β6Weighti + β7Heighti + β8ImplantBrandi+




β18SmokerStatusi + β19AlcoholStatusi + bi + εij,
(4.4)
where logit(HHS)ij is the logit transformed HHS of observation j for the i-th patient.
The explanatory variables used in Equation 4.4 have been previously outlined in Chapter
3. The random effects, bi, are normally distributed: N(0, d
2). The errors, εij, are also
normally distributed. Again we note that all explanatory variables, excluding follow-
up time, are not time-dependent. Therefore, they are all baseline variables or averaged
variables, in the case of weight and height. Since the model in Equation 4.4 is a random
intercept model it allows for a random shift around the intercept resulting in fitted lines
that are parallel to the population fitted line.
Let’s suppose that alternatively there is a relationship between HHS and follow-up
time which is different for each patient. In this case, we can apply the mixed-effects
model with not only a random intercept, but also a random slope. The random intercept
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and slope model is specified as,
logit(HHS)ij =α + β1Sexi + β2Agei + β3FollowupTimeij + β4FollowupTime
2
ij+
β5Sidei + β6Weighti + β7Heighti + β8ImplantBrandi+




β18SmokerStatusi + β19AlcoholStatusi + bi0 + bi1FollowupTimeij + εij
(4.5)
where the term bi0 is the random intercept and bi1 is the random slope for follow-up
time. Comparing the two models shown in Equations 4.4 and 4.5, along with a generalised
least squares model, allows us to determine the optimal random effects structure.
The AIC values for the random intercept, random intercept and slope, and generalised
least squares model are 6288.1, 6260.8 and 6637.5 respectively. The likelihood ratio test
comparing the random intercept model and the random intercept and slope model indi-
cates that the model with the random slope and intercept is preferable, with L = 30.90
(df = 34, p < 0.001). Therefore, the optimal random effects structure is a random slope
and intercept, as shown in Equation 4.5.
Next we check whether we have homogeneity of variance for the model shown in Equa-
tion 4.5. Figure 4.1 displays diagnostic plots for this model. This includes scatterplots of
the residuals against fitted values, and the residuals against the continuous quantitative
explanatory variables, such as age and weight. Also included are the side-by-side boxplots
of residuals against the explanatory variables, such as gender, sum of comorbidities and
smoker status. The fitted against residuals plot shows a distinct linear line in the top right




































































































































































































































































































































































































































































































50 Chapter 4. Mixed-Effects Modelling
of the plot. We can again isolate these residuals as being the residuals for observations
of HHS that are 100. Nevertheless, the remainder of the residuals, for all other values of
HHS, fit the assumptions of the model. Overall these plots do not show any clear violation
of homogeneity.
To calculate the optimal model for the explanatory variables we fit the same model,
Equation 4.5, but with ML and use the likelihood ratio test to determine the least sig-
nificant term. This term is then removed from the model. This process is repeated until
all the explanatory variables within the model are significant at the 5% level. The model
that is selected is the optimal model and is written as,
logit(HHS)ij =α + β1Sexi + β2Agei + β3FollowupTimeij+
β4FollowupTime
2
ij + β5Weighti + β6NumberOfComorbsi+
β7AVNi + β8PlaceOfResidencei + β9SmokerStatusi+
bi0 + bi1FollowupTimeij + εij.
(4.6)
The estimated parameters are calculated using REML and are shown in Table 4.1,
including the components of variance estimators. The slope for gender is 0.40, which
indicates that the logit HHS for an observation from a male patient is estimated to be
0.40 higher than a female patient, adjusting for all the other covariates in the model.
Indicating that being male is associated with less pain and better function after THR
surgery. Having two, three or four or more comorbidities, instead of no comorbidities,
is associated with a lower HHS. Living home alone with external support is associated
with a lower HHS than patients who live independently. Likewise living at home with
others with external support or living in a nursing home (part of the category ‘other’) is
associated with a lower HHS than living independently.
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Table 4.1 also shows that the slope for the follow-up time is 0.08 and the slope for the
quadratic term for follow-up time is −0.002. Therefore, if the follow-up time is between
0 and 40 months then time is associated with a higher HHS. In contrast, if the follow-up
time is greater than 40 months than time is associated with a lower HHS. This indicates
that more time after surgery is associated with less pain and better function, up until 40
months.
The coefficient for moderate smoker status is -0.42. This means that the logit HHS for
a patient who moderately smokes is estimated to be 0.42 lower than a patient who does
not smoke at all, adjusting for all the other covariates in the model. This indicates that
patients who do not smoke are associated with less pain and better function, after THR
surgery, compared to patients who moderately smoke. Patients with a heavier weight are
associated with a lower HHS, as are patients who suffer from AVN (avascular necrosis).
These results suggest that to increase a patient’s chance of less pain and better function
after surgery it may be beneficial to decrease weight and be a non-smoker. In regards to
the results for the variable place of residence, this is most likely indicative of a patient’s
frailty. For example, if a patient is home with others or needs support then they are
more likely to be frail than a patient who lives independently. Dependent and frail
patients are associated with a lower HHS after THR surgery, compared to patients who
live independently.
In relation to the components of variance, shown in Table 4.1, we see that the slope and
intercept variance estimates are significantly lower than the within patient residual. The
random intercept, bi0, is normally distributed with mean 0 and variance 0.72
2. This is less
than the residual term, εij, which has variance 0.96
2. Using these values we can determine
that the correlation between observations from the same patient is 0.722/(0.722+0.962) =
0.36. Also we see that the correlation between the random intercept and slope estimates
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Parameter Estimate p-value
Fixed Effect Intercept (mean change in logit 2.53 <.0005
Estimates HHS at 0 months)
Slope (months after surgery) 0.08 <.0005









Four or more -0.35 0.04
Place of Residence
Home alone & external support -0.37 0.02
Home with others & independent -0.06 0.57






Component of Within Patient Residual 0.96
Variance Estimates Between Patient Residual (intercept) 0.72
Between Patient Residual (slope) 0.01
corr(bi0, bi1) 0.99
Table 4.1: Model parameters for HHS; Number of observations: 2049. Number of patients:
808.
is high. This is due to there being little variation within the grouping (random) variables.
To further validate the model heterogeneity was examined. Figure 4.2 displays diag-





























































































































































































































































































































































































54 Chapter 4. Mixed-Effects Modelling
nostic plots for the random intercept and slope mixed-effects model defined in Equation
4.6. This includes scatterplots of the residuals against fitted values, and the residuals
against the continuous quantitative explanatory variables, such as age and weight. Also
included are the side-by-side boxplots of residuals against the explanatory variables, such
as gender, sum of comorbidities and smoker status. This figure shows that the assumption
of homogeneity is satisfied, as there does not appear to be any clear trends within the
residuals of the model.
Our optimal model at this stage contains the nominal categorical variables place of
residence, AVN and gender. The ordinal categorical variables within the model are the
number of comorbidities and smoking status. The continuous quantitative explanatory
variables are the baseline age, baseline weight and follow-up time of a patient. Since there
is no clear pattern if the residuals are plotted against follow-up time, then independence
is assumed, see Figure 4.2.
The plot of the residuals against fitted values for the model described in Equation 4.6
is shown in Figure 4.3. The blue points are HHS measurements that are 100. The red
points are the HHS measurements that are not 100. The darker shaded points indicate
areas of higher density while the lighter shade indicates lower density. Therefore, this
model fails to effectively predict values about the upper bound of the HHS. Instead the
model consistently underestimates these observations as it does not predict any value
that is over the HHS upper bound of 100. Nevertheless, the remainder of the residuals
are fairly normally distributed. To check further if the assumptions of the model were
satisfied we explored the residual distributions for each level of the explanatory variables
within the model. We stratify these analyses by sex for further insights into the residual
distributions.
Figure 4.4 is a plot of the residuals for each gender and AVN status. 1 indicates not






















Figure 4.3: Plot of the standardized residuals against fitted values. The blue points are
HHS measurements that are 100. The red points are the HHS measurements that are not
100. The darker shaded points indicate areas of higher density while the lighter shade
indicates lower density (n=808).
suffering from AVN while 2 indicates that a patients suffers from AVN. M indicates a male
patient while F indicates a female patient. The solid lines are LOESS smoothers to show
the overall trend of the residuals. This plot allows for the evaluation of the distribution of
the conditional Pearson residuals across each follow-up time for both genders and status
of AVN. The variability of the residuals does not seem to vary greatly. Though the plot
does reveal some outliers, i.e., residuals larger than four for patients without AVN. These
outliers all correspond to HHS measurements of 100, which as we discussed previously,
do not behave well in this model. Therefore, these outliers are present in both genders
and across all time points up until 24 months when the number of observations begins to
decrease across the dataset.

























Figure 4.4: Plot of the residuals against time separated by gender and AVN status. 1
indicates not suffering from AVN while 2 indicates that a patients suffers from AVN. M
indicates a male patient while F indicates a female patient. The solid lines are LOESS
smoothers to show the overall trend of the residuals (n=808).
We also note in Figure 4.4 that we see a clustering of residuals around 3, 12 and 24
months. This is because the clinic normally schedules a follow-up after surgery at 3, 12
and 24 months. Therefore, we would expect to see this clustering in the residuals when
they are plotted against time.
Figure 4.5 is a plot of the residuals against time separated by gender and smoker status.
1 indicates non-smoker, 2 indicates light smoker and 3 indicates heavy smoker. The solid
lines are LOESS smoothers to show the overall trend of the residuals. This plot reveals
outliers with residuals greater than 4, which again corresponds to HHS measurements of
100. There appears to be some non-linearity in the residuals for heavy smokers across






























Figure 4.5: Plot of the residuals against time separated by gender and smoker status. 1
indicates non-smoker, 2 indicates light smoker and 3 indicates heavy smoker. The solid
lines are LOESS smoothers to show the overall trend of the residuals (n=808).
both genders. This is most likely reflective of the lack of observations within this category.
Nevertheless, the residuals appear to be fairly randomly spread across both genders and
each smoking status.
Another variable that was of significance within the optimal mixed-effects model was
place of residence. Figure 4.6 shows a plot of the residuals against time separated by
gender and place of residence. 1 indicates home alone & independent, 2 indicates home
alone & external support, 3 indicates home with others & independent, 4 indicates home
with others & support and 5 indicates ‘other’ living situation. The solid lines are LOESS








































Figure 4.6: Plot of the residuals against time separated by gender and place of residence.
1 indicates home alone & independent, 2 indicates home alone & external support, 3
indicates home with others & independent, 4 indicates home with others & support and 5
indicates other living situation. The solid lines are LOESS smoothers to show the overall
trend of the residuals (n=808).
smoothers to show the overall trend of the residuals. Levels 1, 3 and 4 of the place of
residence variable show no clear patterns in the residuals. In contrast, we see that level 2,
home alone & external support, shows some linear trend for the male patients. But this
is also reflective of the lack of observations within these categories, as there are less males
than females who are home alone & have external support. Patients who are recorded as
having a place of residence that is not specified, those listed as ‘other’, are few, particularly
for males.
Figure 4.7 displays a plot of the residuals versus follow-up time for each sex and








































Figure 4.7: Residuals versus follow-up time for each sex and number of comorbidities com-
bination. Where 0 indicates not having any comorbidities, 1 indicates have one comor-
bidity, etc. A LOESS smoother with a span of 0.5 was fitted to aid visual interpretation
(n=808).
number of comorbidities combination. Where 0 indicates not having any comorbidities,
1 indicates have one comorbidity, etc. A LOESS smoother with a span of 0.5 was fitted
to aid visual interpretation. We see that across both genders, and different numbers of
comorbidities, patient residuals do not show any real pattern. Outliers are still present
within the residuals, which are again the HHS measurements of 100. The residuals for
females that have four or more comorbidities may potentially not be linear but this is
most likely due to the lack of observations, particularly between 3 and 12 months, which
may create the non-linear pattern.
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Figure 4.8: Normal Q-Q plots of the conditional Pearson residuals for each gender for the
model in Equation 4.6 (n=808).
To further investigate the assumptions of the optimal mixed-effects model normal Q-Q
plots were explored. Figure 4.8 shows the normal Q-Q plot of the conditional Pearson
residuals separated by gender. The normal Q-Q plots do show some deviations from a
linear trend at the right upper tail. This is a reflection of the poor behaviour of the HHS
measurements of 100, as discussed before. These observations create a strong deviation
from the linear trend we expect to see in a normal Q-Q plot.
We can also look at the normal Q-Q plot of the predicted random effects (random
intercept and slope). The effects are estimated using BLUPs (best linear unbiased pre-
dictors). These are the conditional expectations of the random effects, given the observed
responses and will be discussed further in Section 4.2. The resulting Q-Q plot is shown
in Figure 4.9 and again displays a non-linear tail while the majority of the points lie on
the linear line. Again these points, on further investigation, are related to HHS measure-
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Figure 4.9: The normal Q-Q plot of the predicted random intercepts and slopes for the
model in Equation 4.6. Left: normal Q-Q plot of the predicted random intercepts; Right:
normal Q-Q plot of the predicted random slopes (n=808).
ments of 100. Nevertheless this plot may not necessarily reflect the true distribution of
the random effects. This is because the observed distributions of the conditional expecta-
tions of the random effects, given the observed response, does not necessarily reflect the
true distribution of the random effects [11]. However they are still helpful at identifying
outlying values that warrant further investigation.
Many plots have been shown regarding the relationship between explanatory variables
and the residuals. In most cases, we assume independence because we cannot see a clear
pattern when the residuals are plotted against follow-up time. However, in some cases
there appeared to be a potential pattern in the residuals. Though we suspect this is due
to small observation numbers in specific groups we still want to investigate this further.
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To do this we fit an additive mixed model, which is written as,
logit(HHS)ij =α + β1Sexi + β2Agei + f(FollowupTimeij)+
f(FollowupTime2ij) + β5Weighti + β6NumberOfComorbsi+
β7AVNi + β8PlaceOfResidencei + β9SmokerStatusi+
bi0 + bi1FollowupTimeij + εij.
(4.7)
where the term f(FollowupTimeij) and f(FollowupTime
2
ij) are now smoothing splines.
It is expected that the shape of the smoother is a straight line if the linear mixed-effects
model is appropriate.
Figure 4.10 displays the estimated smoother for the term f(FollowupTimeij) within
the additive mixed model shown in Equation 4.7. The solid line is the estimated smoother
and the dotted lines are the 95% point-wise confidence bands. The horizontal axis shows
the follow-up time in months and the vertical axis the contribution of the smoother to
the fitted values.
This figure shows that the relationship between follow-up time and the contribution
of the smoother to the fitted values is linear. The estimated regression parameters for
the additive mixed model are similar to the linear mixed-effects model. The AIC for this
model is 8522 while the AIC for the previous model is 8605. The smoother is significant
and has one degree of freedom for the f(FollowupTimeij) term. The degrees of freedom
for the f(FollowupTime2ij) term is slightly more at 3.5. As a result, there appears to be
no pattern in the residuals and this mixed-effects model. This supports the mixed-effects
model in Equation 4.6.
We will now look closer at this model’s ability to predict HHS observations for patients
with varying levels of information available. For example, for patients who have some HHS
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Figure 4.10: Estimated smoother for the additive mixed model. The solid line is the
estimated smoother and the dotted lines are the 95% point-wise confidence bands. The
horizontal axis shows the follow-up time in months and the vertical axis the contribution
of the smoother to the fitted values (n=808).
observations, and patients with only baseline information.
4.2 Prediction and Cross-Validation
In this section, we discuss prediction and cross-validation methods for the optimal mixed-
effects model outlined in Equation 4.6. Prediction is important for two reasons. Firstly,
it helps us predict what a patient’s HHS might be at a certain point after surgery. This
includes predicting future observations for patients who already have some measured HHS
observations. This also includes predicting the HHS of new patients, who are not within
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Prediction
Group A: Population level
Group B: Individual level
Existing patient
When estimation model frame includes:
All observations
All but the last observation
New patient
Using the BLUPs of the random effects of:
A random patient
An average patient
A patient with similar characteristics
All patients
Figure 4.11: Flow chart of prediction methods explored at both a population and indi-
vidual level.
the estimation model frame. Secondly, prediction allows us to check that the model is
appropriate. We can do this through comparison of the predicted values to the true
observations, through cross-validation. In addition, an analysis of the variability of the
parameter estimates will be explored to further validate the model. Together, this helps us
understand the limitations of this model and how effective it is at predicting postoperative
patient pain and function based on preoperative factors.
Prediction for mixed-effects models comes with some challenges. One of the advantages
of mixed-effects models is the inclusion of a random intercept or slope term to take into
account the correlations within patient measurements. This means that we can make
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predictions at the patient level, or at the population level. Figure 4.11 displays a flow
chart of the different methods of prediction that are explored in this section. These
are population and individual level prediction. When making individual patient level
predictions there are numerous approaches. Figure 4.11 shows that these approaches
are dependent on whether you are predicting the HHS for a patient that exists in the
estimation model frame or for a new patient.
Prediction at a population level (Group A in Figure 4.11) estimates the marginal
expected value of the response. For example, the marginal expected value of the corre-




where xh is a vector of the fixed effects and β is the estimated coefficients of the fixed
effects.
Predicted values at the patient level (Group B in Figure 4.11) are the conditional
expectation of the response given the random effects. For example the patient level
predictions can be written as,
E[yh(i)|bi] = xThβ + zh(i)Tbi,
where zh(i) is a vector of the random effects and bi is the estimated random effects
associated with the i-th patient [24].
To help make predictions at both the population and individual level we use condi-
tional estimates and BLUPs. At a population level, the BLUPs of the expected values
are obtained by replacing β with its conditional estimate, β̂(θ). At an individual level
the conditional expectations given the random effects are obtained by making a similar
replacement but also replacing the random effects with their BLUPs. For example, the
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E[yh(i)|bi] = xTh β̂(θ) + zh(i)T b̂i(θ).
The unknown parameters, θ, are replaced by the REML estimate for maximum like-
lihood, providing us with BLUPs of the expected values [24].
This implies that a patient that the model has trained on has associated BLUPs, which
can be extracted from the model and used to make further predictions for that patient. A
patient that is not in the estimation model frame does not have this and as a result there
are different ways in which we can predict HHS. Therefore, these two situations need to
be treated differently, as shown in Figure 4.11 with the separation of new and existing
patients.
For existing patients we can compare the predictions made when we have varying
amounts of information, as shown in Figure 4.11. We begin by looking at prediction if
we have all patient follow-up measurements within the estimation model frame. This
is then compared to prediction of a patient’s last HHS observation given that their last
observation is not within the estimation model frame.
For new patients one method of prediction is to solely use the estimated coefficients
for the fixed effects to predict a patient’s HHS. Another method is to use the BLUPs
of the random effects of a patient that is in the estimation model frame to predict the
HHS for a new patient. The patient that is already within the estimation model frame
can be selected at random, they can be a representation of an average patient in the
population or they can have similar characteristics to the new patient [17]. For example,
if a new patient is female and does not smoke then we could find another patient within
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the estimation model frame with these characteristics and use the BLUPs of the random
effects for prediction.
The last method that will be addressed, as shown in Figure 4.11, is comparing the
prediction of a new patient across all possible BLUPs of the random effects within the
model. Therefore, presenting the variability of prediction depending on which patient’s
BLUPs for the random effects are applied.
4.2.1 Group A: Population Level
Firstly we will look at population level prediction. Though this may not be the most
accurate method of prediction it can still be useful when comparing two models, through
cross-validation. It can help us understand the limitations of the model and inform us of
the potential limitations regarding prediction.
One method is to use population level prediction to perform k-fold cross validation.
This method of cross-validation takes the dataset and partitions it randomly into k roughly
equal groups. In our case, we chose k = 10 therefore we partition the rows into 10 groups.




of the total dataset. Each group contains 10% of
the dataset and becomes a test group. The complementary 90% of the dataset, for each
group, trains the model. Therefore, this method takes a random sample of 10% of the
dataset and trains the model on the remaining 90%. Then it uses this model to predict on
the 10%, using only the fixed effects and therefore predicting population means. Finally,







for each 10 test and training sets, where n is the total number of HHS measurements.
68 Chapter 4. Mixed-Effects Modelling


























Figure 4.12: Plot of the mean squared error of 1000 simulations of k-fold cross validation.
The solid lines are LOESS smoothers to show the overall trend of the MSEs. Group
A is the optimal model without the random slopes and group B is the optimal model
(Equation 4.6) (n=808).
This process of cross validation was simulated 1000 times for the optimal model. It was
also done 1000 times for the optimal model but only with random intercepts. Therefore,
comparing the random effect structure. Figure 4.12 is a plot of the mean squared error of
1000 simulations of k-fold cross validation. The solid lines are LOESS smoothers to show
the overall trend of the MSEs. Group A is the optimal model without the random slopes
and Group B is the optimal model (Equation 4.6). It is clear that Model B, the model
with both a random intercept and slope, has a lower MSE. A lower MSE indicates that
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the predicted HHS values are closer to the observed values, overall. Therefore, the most
appropriate model is still the optimal mixed-effects model (Equation 4.6).
Cross validation was again completed to compare methods of determining the opti-
mal model. This process was simulated 1000 times for a mixed-effects model that was
determined through stepwise model selection by AIC. Again we found that the optimal
mixed-effects model, defined by Equation 4.6, was the most appropriate as it had a lower
MSE.
Figure 4.12 also shows that there is great variability within the MSE of the optimal
mixed-effects model. Even though Group B has a lower MSE, indicated by the LOESS
smoother, it still has the single highest MSE out of both Model A and Model B. Therefore,
it is important to check the variability within the model, such as the variability of the
estimates.
Figure 4.13 shows a side-by-side boxplot of the distribution of the estimated coef-
ficients of the optimal model, Equation 4.6, for 1000 exponentially weighted bootstrap
simulations. This means that we drew repeatedly from an exponential distribution to cre-
ate bootstrap weights that were applied to the mixed-effects model. Therefore, random
observations were given more weight within the model, for each simulation, to determine
if this had an effect on the variability of the coefficient estimates [30]. Each simulation
had the same variables present as the optimal model, therefore each coefficient had a value
for each cross-validation subsample.
We observe, from Figure 4.13, that the intercept, in particular, varies more than
other variables, over the bootstrap sample. Likewise the coefficient for patients who
smoke heavily appears fairly variable. Nevertheless, this particular factor level is not
significant within the model. We also see that variables such as age and weight have
little variability and lie very close to zero. It is clear that the majority of variables are


















−1 0 1 2 3
Coefficient estimate
Figure 4.13: Boxplots of the distribution of the estimated coefficients of the optimal
model, Equation 4.6, for 1000 exponentially weighted bootstrap simulations (n=808).
associated with a lower HHS, due to the estimated coefficients consistently appearing
below zero, particularly the variables place of residence and number of comorbidities.
Though population level prediction can help us cross-validate our model it is also
important to compare this to patient level prediction. Specifically comparing the predicted
values to the true observations at both the individual and population level.
4.2.2 Group B: Individual Level for Existing Patients
Individual level prediction methods, as shown in Figure 4.11, can be separated by predic-
tion for an existing patient and for a new patient. For an existing patient the estimated
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BLUPs of the random effects for that specific patient can be utilized. Whereas, for a new
patient this is not possible and another approach needs to be applied. Individual level
prediction for a new patient will be discussed later, in Section 4.2.3. In this section we
focus on prediction methods for existing patients. The methods addressed in this section
are outlined in Figure 4.11 in Group B under existing patients. We begin with prediction
for an existing patient, where the estimation model frame includes all of a patient’s HHS
observations.
Figure 4.14 shows the observed and predicted transformed HHS measurements for
16 randomly selected patients, where all predicted follow-up measurements are in the
estimation model frame. The x-axis is the follow-up time and the y-axis is the transformed
HHS. The blue points show the observed HHS measurements for that patient. The blue
lines show the population level prediction and the pink dashed lines show the individual
level prediction, both using the optimal model. Therefore, we can compare the predicted
population mean, calculated solely using the estimated coefficients for the fixed effects,
and the individual patient predictions.
Due to our assumed structure of the model, the population means are shifted for
individual patients by subject specific random intercepts and slopes. Therefore, we see
that the slopes and intercepts of the individual profiles are different across subjects. We
can also note that the predicted population means, shown in the Figure 4.14, increase
very slightly over time.
For some patients the predicted individual profiles deviate from the observed measure-
ments. For example, Subjects 25995 and 20627 show a decrease in the observed values
over time, while the predicted individual patterns suggest an increase in HHS over time.
Despite this, Figure 4.14 shows that individual level prediction is the most appropriate
method of prediction if we wish to get an accurate representation of a specific patient’s
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Figure 4.14: Observed and predicted transformed HHS for 16 random patients using the
optimal model (Equation 4.6). The blue points show the observed HHS measurements
for each patient. The blue lines show the population level prediction and the pink dashed
lines show the individual level prediction (n=16).
predicted HHS. This is important because we need the best predictions for individuals
so that they can seek the best treatment for their specific condition. Though popula-
tion level prediction can help us cross-validate our model it is not as capable of making
representative patient level predictions.
In the previous case we were comparing predicted values to observations that were in





















Figure 4.15: Plot of the predicted against the observed HHS values. This is specifically
prediction of a patient’s last HHS observation given that we only know their previous
observations, for 500 random patients.
the estimation model frame. We are also interested in the case where the model predicts
future HHS observations that are not in the estimation model frame. Let’s consider the
case where we have some information, some follow-up observations for a patient so we can
utilise BLUPs of the random effects for patient level prediction. Therefore, if we refer to
Figure 4.11, this is the case where we have an existing patient but their last observation
is not within the estimation model frame.
To do this we remove a random patient’s final observation from the dataset and then
estimate the model parameters using this subset. Using the new estimated parameters
we then predict the HHS measurement at the time of the patient’s last observation (the
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observation that was removed). These predictions were then compared to the actual HHS





















Figure 4.16: Plot of the observed and predicted HHS measurements for 10 randomly se-
lected patients last observation, given that we know the HHS measurements of earlier
observations. The x-axis is the follow-up time and the y-axis is the transformed HHS.
The dotted lines show the observed patient HHS trajectories. The smaller points are the
observed patient HHS measurements. The larger points are the predicted HHS measure-
ments for the patient’s last observation. The solid line shows the difference between the
predicted and the observed HHS measurements for the patient’s last observation (n=10).
Figure 4.15 is a plot of the predicted against the observed HHS values. This is specif-
ically prediction of a patient’s final observation given that we only know their previous
observations. This plot is the results of 500 simulations, where in each simulation a ran-
dom patient with more than one observation was used for prediction. As we expect, the
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model predicts HHS well in this case, as the points lie close to the reference line. The
model still struggles to accurately predict observed HHS measurements of 100, as shown
by the horizontal line of outliers at the top of Figure 4.15.
Figure 4.16 is a plot of the observed and predicted HHS measurements for 10 ran-
domly selected patients final observation, given that we know the HHS measurements of
their earlier observations. The x-axis is the follow-up time and the y-axis is the trans-
formed HHS. The dotted lines show the observed patient HHS trajectories. The smaller
points are the observed patient HHS measurements. The larger points are the predicted
HHS measurements for the patient’s last observation. The solid line shows the differ-
ence between the predicted and the observed HHS measurements for the patient’s last
observation. This shows that for most patients, within this figure, the predictions are
fairly accurate, as shown by the length of the solid lines. The predictions are particularly
accurate for patients whose HHS does not deviate greatly over time.
Therefore, we can fairly accurately predict a patient’s later observations given that
we have preceding observations. Nevertheless, we are most interested in predicting a new
patient’s HHS trajectory after surgery, based completely on their baseline characteristics.
Or in other words, we are interested in predicting postoperative patient pain and function
based on preoperative factors, such as age and gender. This is explored in the following
section.
4.2.3 Group B: Individual Level for New Patients
To make individual level predictions for new patients we use the BLUPs of the random
effects from other patients that are within the estimation model frame. Nevertheless,
there are numerous ways in which one can select which patient’s BLUPs of the random
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effects to apply to a new patient for prediction. Four such methods will be explored in
this section and are outlined Figure 4.11. These are, a patient selected at random, an
average patient in the population, a patient with similar characteristics to the new patient
or a comparison across all patients [17].
The first method is to pick an observation at random and use that patient’s estimated
random effects to make predictions for a new patient. Nevertheless, selecting a random
patient may not be particularly meaningful. Alternatively, we can use the BLUPs of the
random effects of an average observation. An average observation is the modal observation
for factor variables and the mean value for numeric variables, across all patients. In this
case, the random effect terms are set to the level equivalent to the median effect.
Therefore, we predict using an average observation but we modify the variable values
to see how prediction varies accordingly. This is due to interest in the amount of variation
in predicted HHS trajectories that is caused by changes in the explanatory variables. For
example, we can compare the predictions made for an average patient against an average
patient who we assume is a smoker (as the modal observation is non-smoker). This
comparison shows how the HHS predictions change, for an average patient, if we keep
everything but one variable constant.
Figure 4.17 shows the predicted HHS trajectory for different genders and smoking
statuses. The transformed HHS is on the y-axis and the follow-up time is on the x-axis.
Each plot corresponds to either a male or female patient (indicated by the M and F).
The smoking status of the patient is shown by a 1, which indicates a non-smoker, or a 2,
which indicates a smoker. The smoker status of 3 (heavy smoker) is not considered here
due to it’s lack of significance within the optimal model. In this case, we are using an
average observation to determine the random effect BLUPs for individual level prediction.
The coloured lines display the predicted trajectories for the patient depending on the

































Number of comorbidities 0 1 2 3 4+
Figure 4.17: Plot of the predicted HHS trajectories against follow-up time using the
estimated parameters of an average patient. The characteristics of this patient are altered
to compare gender and smoking status. The smoking status 1, indicates a non-smoker,
and 2, indicates a smoker. The coloured lines indicate the predicted HHS trajectories
given the number of comorbidities the patient suffered from. The solid black line denotes
where HHS is equal to 70 and is the line between a poor HHS, below the line, or a good
HHS, above the line.
number of comorbidities that a patient suffers from, at the point of surgery. The solid
black horizontal line denotes where the HHS equals 70 and is the line between what is
considered a poor HHS, below the line, or a good HHS, above the line [12].
From Figure 4.17 we see that in all cases there is a predicted decrease in HHS from 24
months to 48 months. This may be because patients who recover well from the surgery
have less follow-up measurements after 24 months, while patients who are still experi-
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encing physical limitations are more likely to continue seeking help beyond 24 months
after the surgery. Nevertheless we do see a predicted increase in HHS between 0 and
24 months, with the fastest improvement occurring between 0 and 12 months. It is also
clear that patients who smoke are predicted to have a lower HHS than patients who are
non-smokers. Males are associated with a higher HHS. The number of comorbidities that
a patient suffers from does have an effect on their predicted HHS trajectory. Having one
or no comorbidities is associated with the highest HHS. Having 3 or 4 or more comorbidi-
ties is associated with a lower HHS, and these two levels appear to have fairly identical
trajectories.
Not only can we use BLUPs of the random effects of an average patient but we can use
BLUPs of the random effects from random patients to understand the variability of this
prediction. Figure 4.18 shows the predicted HHS trajectory for four randomly selected
patients. Therefore, each patient has individual estimated random effects. This is evident
by the different slopes and intercepts that are seen in the four plots. The coloured lines
indicate the predicted trajectories given the number of comorbidities the patient suffered
from. The solid black line denotes where HHS is equal to 70 and is the line between a
poor HHS, below the line, or a good HHS, above the line.
Across all four patients we see that the number of comorbidities does affect the pre-
dicted HHS trajectory. Suffering from less comorbidities is associated with less pain and
better function. Patient 37129 appears to have the lowest HHS in Figure 4.18. This
patient is aged 62 years and is a female of weight 52 kg. They do not suffer from AVN,
do not smoke and only suffer from two comorbidities. As a result they live at home with
others and are independent. In comparison, the patient with the highest HHS is patient
35506. This patient has the same characteristics as patient 37129 except they are aged
67 years, weigh 61 kg and only suffer from one comorbidity. Nevertheless, there is a stark
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Figure 4.18: Plot of the predicted HHS trajectories against follow-up time using the
estimated parameters of four randomly selected patients. The coloured lines indicate the
predicted HHS trajectories given the number of comorbidities the patient suffered from.
The solid black line denotes where HHS is equal to 70 and is the line between a poor
HHS, below the line, or a good HHS, above the line.
difference in their trajectories due to the estimated random effects, which are reflective of
the observed HHS measurements.
In Figure 4.18 there is no visible difference between the predicted HHS trajectory for
patients with one or two comorbidities. Yet the biggest difference between the patient
with the highest and lowest HHS trajectory is the number of comorbidities that they
suffer from. If we look closer at the HHS observations attached with patient 37129 and
patient 35506 we see that the first HHS observation for patient 37129 is significantly lower
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than patient 33257. Therefore, an initial HHS observation can be crucial in obtaining an
accurate predicted HHS trajectory. This is because the patient specific estimated random
effects that help inform these predictions, make them significantly more representative.
Unfortunately, it may not always be possible to obtain an initial HHS measurement that
can be used for prediction.
To address the variability in prediction that occurs, depending on how we select the
appropriate estimators for the individual random effects, we can look at the variation
in prediction across patients. Therefore, we use the third method for individual level
prediction of a new patient, shown in Figure 4.11. This method uses the BLUPs of the
random effects of patients with the same characteristics as the new patient. This means
that we look at how prediction varies if we use all available BLUPs of the random effects,
within the subset of patients that have similar characteristics to the new patient.
For example, if a patient presents for a THR they may have the following character-
istics:
• Female, 65 years, 70 kg, lives at home and is independent, non-smoker, does not
suffer from AVN and suffers from two comorbidities.
We can draw out 100 random patients with similar characteristics and compare the
difference in the predicted HHS trajectories to determine the most likely trajectory for
that patient. Figure 4.19 is a plot of the predicted HHS trajectories against follow-up time
using the estimated parameters of 100 patients with similar characteristics to the specified
new patient. By similar characteristics, we mean, they have the same gender, place of
residence, smoker status, AVN status and number of comorbidities. The coloured lines
show each patient’s predicted HHS trajectory. The solid black horizontal line denotes
where HHS is equal to 70 and is the line between a poor HHS, below the line, or a good





















Figure 4.19: Plot of the predicted HHS trajectories against follow-up time using the
estimated parameters of 100 patients with similar characteristics to a new patient. The
coloured lines show each patient’s predicted HHS trajectory. The solid black horizontal
line denotes where HHS is equal to 70 and is the line between a poor HHS, below the line,
or a good HHS, above the line. The solid black curved line denotes the LOESS smoother
for all predicted trajectories.
HHS, above the line. The solid black curved line denotes the LOESS smoother for all
predicted HHS trajectories.
Nevertheless, patients with different ages or weights, the variables we did not specify,
may be creating the variability in the predicted HHS trajectories. To check this we restrict
predictions to patients that are five years older or younger than the new patient and 5 kg
heavier or lighter in weight. This restricted the dataset to four patients. We are interested
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Figure 4.20: Plot of the predicted HHS trajectories against follow-up time using the
estimated parameters of 100 patients with similar characteristics to a new patient. The
coloured lines show each patient’s predicted HHS trajectory. The solid black horizontal
line denotes where HHS is equal to 70 and is the line between a poor HHS, below the line,
or a good HHS, above the line. The solid black curved line denotes the LOESS smoother
for all predicted trajectories.
Figure 4.20 is a plot of the predicted HHS trajectories against follow-up time using
the estimated parameters of four patients with almost identical characteristics to a new
patient. The coloured lines show each patient’s predicted HHS trajectory. The solid
black horizontal line denotes where the HHS is equal to 70 and is the line between a
poor HHS, below the line, or a good HHS, above the line. The solid black curved line
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denotes the LOESS smoother for all predicted trajectories. The smoother line is slightly
lower in Figure 4.20 than in Figure 4.19 due to the increased specificity. This shows that
selecting for specific characteristics can have an effect on the predicted HHS trajectory.
Nevertheless, there is still a significant amount of variability. This variability is largely
explained by the inclusion of a random intercept and therefore having at least one HHS
observation can significantly improve prediction.
From this exploration it is clear that even among patients with similar character-
istics the predicted trajectories were variable. Therefore, to address the variability in
predictions that occurs, depending on how we select the appropriate estimators for the
individual random effects, we use the last method stated in Figure 4.11. This method
examines the variation in prediction across all patients. This shows us how the predic-
tion varies if we use all available BLUPs of the random effects and apply them to a new
patient. Furthermore, we can compare these predictions at different factor levels within
the explanatory variables.
Figure 4.21 displays the predicted HHS at 24 months after surgery. The x-axis is
the patient ID. Each individual patient’s BLUPs for the random effects is used but they
are assumed to have the characteristics of an average patient. Therefore, comparing
the variability in the prediction of the HHS at 24 months if all patients are assumed to
have the same characteristics as an average patient. The coloured smoother lines show
the average HHS for patients at 24 months given the number of comorbidities that they
suffer from. This again confirms that suffering from more comorbidities is associated with
a lower HHS. We also see that patients that suffer from no comorbidities have a very
similar predicted HHS, at 24 months, to patients who suffer from one comorbidity.
Figure 4.21 shows that the effect of both the intercept and the number of comorbidities
slope on each patient simultaneously affect our predicted value. This results in the multi-
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Figure 4.21: Plot of the predicted HHS at 24 months after surgery. The x-axis is the
patient ID. Each individual patient BLUPs for the random effects is used but they are
assumed to have the characteristics of an average patient (mean and mode of predictor
variables). The coloured smoother lines show the average HHS for patients at 24 months
given the number of comorbidities that they suffer from. The solid black line separates
HHSs that are good, above the line, and poor, below the line.
ple lines for predicted values across all patients not being parallel, instead they resemble
noise.
Figure 4.22 shows the predicted HHS at 24 months after surgery. This plot compares
the variability in the prediction of the HHS at 24 months if all patients are assumed to
have the same characteristics as an average patient. The coloured smoother lines show the
average HHS for patients at 24 months given a patient’s smoker status. We note that 2
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Figure 4.22: Plot of the predicted HHS at 24 months after surgery. The x-axis is the
patient ID. Each individual patient’s BLUPs for the random effects is used but they are
assumed to have the characteristics of an average patient (mean and mode of explanatory
variables). The coloured smoother lines show the average HHS for patients at 24 months
given a patient’s smoker status. The solid black line separates HHSs that are good, above
the line, and poor, below the line.
indicates that a patient smokes and 1 indicates that a patient does not smoke. This again
confirms that smoking is associated with a lower HHS than non-smoking. The separation
between smoker statuses is quite distinct.
Figure 4.23 shows the predicted HHS at 24 months after surgery. This plot compares
the variability in the prediction of the HHS at 24 months if all patients are assumed to
have the same characteristics as an average patient. The coloured smoother lines show
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Figure 4.23: Plot of the predicted HHS at 24 months after surgery. The x-axis is the
patient ID. Each individual patient’s BLUPs for the random effects is used but they are
assumed to have the characteristics of an average patient (mean and mode of predictor
variables). The coloured smoother lines show the average HHS for patients at 24 months
given a patient’s place of residence. The solid black line separates HHSs that are good,
above the line, and poor, below the line.
the average HHS for patients at 24 months given a patient’s place of residence. This figure
confirms that patients who need external support (level 2, 4 and 5) are associated with a
lower HHS at 24 months. While patients who can live independently (level 1 and 3) are
associated with a higher HHS.
We can use this method of prediction to compare the predicted HHS at different
follow-up times. Figure 4.24 shows the predicted HHS at 0, 3, 12, 24 and 48 months
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Figure 4.24: Plot of the predicted HHS at 0, 3, 12, 24 and 48 months after surgery. The
x-axis is the patient ID. Each individual patient’s BLUPs for the random effects is used
but they are assumed to have the characteristics of an average patient (mean and mode
of predictor variables). The coloured smoother lines show the average HHS for patients
at each follow-up time. The solid black line separates HHSs that are good, above the line,
and poor, below the line.
after surgery. This plot compares the variability in the prediction of the HHS at these
times if all patients are assumed to have the same characteristics as an average patient.
The coloured smoother lines show the average HHS for patients at the different follow-
up times. Fortunately, this shows that the worst HHS is predicted to occur at 0 months.
Likewise the best predicted HHS appears to occur at 24 months. Unfortunately, it appears
as though the HHS lowers after 24 months as the predicted HHS at 48 months is similar
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to 3 months after surgery. Again this could be because patients who recover well from the
surgery have less follow-up measurements after 24 months, creating a bias in the predicted
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Figure 4.25: Plot of the predicted HHS at 0, 3, 12, 24 and 48 months after surgery. The
x-axis is the patient ID. Each individual patient’s BLUPs for the random effects is used
but they are assumed to have the characteristics of an average patient (mean and mode of
predictor variables), except each patient is set to being a smoker. The coloured smoother
lines show the average HHS for patients at each follow-up time. The solid black line
separates HHSs that are good, above the line, and poor, below the line.
It is also interesting to see how the predicted HHS at different follow-up times is
effected by assuming different values for predictor variables. For example, Figure 4.25
shows the predicted HHS at 0, 3, 12, 24 and 48 months after surgery where each patient
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is set as smoking. The coloured smoother lines still show the average HHS for patients
at the different follow-up times. Again we see that the HHS appears to improve up until
24 months. At this point the HHS is predicted to decrease until at 48 months a patient
is back at the same level of pain and function they experienced at 3 months after THR
surgery.
Comparing Figure 4.24 and Figure 4.25, it is clear that patients who smoke are as-
sociated with a lower HHS at each time point, compared to patients who do not smoke.
What is concerning is that at 48 months a patient’s HHS is predicted to be on the edge of
what is classified as ‘good’ pain and function. Therefore, it is predicted that this surgery
will leave a patient of this demographic with potentially poor pain and function after 48
months.
4.2.4 Summary
On average most patients are predicted to be within the ‘good’ pain and function bracket
(HHS of 70 or above) at 24 months after surgery. Nevertheless, using these various meth-
ods of prediction we can get a more accurate representation of a patient’s specific HHS
trajectory based on their baseline characteristics. Specifically, appropriately using BLUPs
for the random effects of patients that are already within the estimation model frame to
predict new patient’s HHSs. It is also optimal to have at least one HHS measurement to
aid in prediction, due to the effect of the intercept, though this is not always practical.
Population level prediction was the fastest and also the simplest method of prediction.
Nevertheless, individual level prediction was more representative of the THR dataset. For
existing patients, prediction is fairly simple and does not have the same limitations as
prediction for new patients. The most representative way to approach prediction for a new
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patient is to use the BLUPs of the random effects of patients with similar characteristics
while also checking the variability in the prediction over all possible BLUPs of the random
effects. This approach to prediction is limited by the sample size. Therefore, if a sample
is not large enough to have a number of patients with similar characteristics then using
an average patient’s BLUPs of the random effects is optimal.
Throughout this chapter we have looked in depth at determining an optimal mixed-
effects model and using it for prediction. Nevertheless, we have only looked at mixed-
effects models with the response variable of HHS. Within the dataset there is a subset of
patients who have a recorded baseline HHS measurement. Using this baseline measure-
ment the change in HHS can be determined for a subset of patients. Therefore, we can




Since the focus of this work is the analysis of the Harris hip score (HHS), as a measurement
of a patient’s pain and function, the change in HHS is of interest. In previous analyses,
preoperative factors such as age and gender have been used to inform postoperative re-
covery. Furthermore, the baseline HHS measurements can be used to explore the effect
of preoperative factors on the change in a patient’s pain and function after surgery. In
this chapter we will again used mixed-effects modelling to explore the change in HHS for
THR patients.
Our study sample consists only of patients who have a valid baseline HHS measure-
ment. A baseline HHS is classified as a HHS that is measured between zero to 12 months
before their date of surgery, inclusive of zero and 12. This definition is based on advice
given by clinicians. Even though the baseline measurement is inclusive of up to a year
before surgery we note that 91.4% of the baseline measurements occur at time zero. This
is because clinicians try and assess the baseline measurements as close to the time of
surgery as possible.
The sample size of the sub-study is 897 patients as this is the number of patients with
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a valid baseline HHS that we can use to calculate the change in HHS over time. To do this
the follow-up HHS measurement was anchored on the baseline HHS. For example, let’s
say a patient with a baseline HHS of 70 has two follow-up HHS measurements of 60 and
65, respectively. The change in HHS for this patient is 10 and 5, for the first and second
observations, respectively. Therefore, by subtracting the follow-up HHS for an individual
patient from their specific baseline measurement we have a new response variable, change
in HHS.
Patient Demographics Baseline Follow-up
n of patients 897 2280
Mean (SD) age (yrs) 67.2 (12.3) 67.0 (12.3)
Mean (SD) weight (kgs) 80.5 (18.3) 78.6 (17.7)
Mean (SD) height (cms) 166.2 (12.0) 165.4 (12.1)
Female (n,%) 485 (54.1) 1341 (58.8)
Male (n,%) 412 (45.9) 939 (41.2)
Diagnosis (n,%)
Osteoarthritis 668 (74.5) 1734 (76.1)
AVN 75 (8.4) 182 (8.0)
Rheumatoid arthritis 21 (2.3) 57 (2.5)
Number of Comorbidities (n,%)
None 177 (19.7) 704 (30.9)
One 263 (29.3) 745 (32.7)
Two 221 (24.6) 497 (21.8)
Three 125 (13.9) 240 (10.5)
Four or more 61 (6.8) 94 (4.1)
Table 5.1: Summary of the distribution of demographic variables for baseline and follow-
up data. Where the baseline data consists of observations measured between zero and 12
months before surgery. The Follow-up data consists of observations that occurred after
surgery (n = 897).
When we take a subset of the dataset, such as this baseline data, it is important to
check if the subset has a particular demographic profile that is not a true reflection of
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the dataset as a whole. Table 5.1 shows a comparison of the distribution of demographic
variables for both the 897 baseline patients and 2280 patients with follow-up data. This
shows that the distribution of demographic variables is relatively consistent across the
baseline and the follow-up data, with the mean age being approximately 67 years. There
is a slightly lower percentage of females within the baseline sample. The proportion of
patients with only one comorbidity is less within the baseline dataset (20%) than the
follow-up dataset (31%).
To further check our definition of baseline measurements including a year before
surgery a comparison of the demographic characteristics was completed. This compared
the baseline data that was collected at the time of surgery and the baseline data that
was collected within the year before surgery. There appeared to be no significant differ-
ence between the distribution of variables within those two groups. This supports our
definition of baseline including a year before surgery.
For example, Figure 5.1 displays a side-by-side boxplot of the distribution of age for
the baseline data (≤0) and follow-up data (> 0). The baseline data is separated into
those at the time of surgery (= 0) and those in the year preceding surgery (< 0). Fainter
points indicate a low density of outliers while darker points indicate a high density of
outliers. The follow-up data appears to have a higher density of outliers that are younger.
This is most likely a reflection of the difference in sample size between the follow-up data
and baseline data. Therefore, age is distributed similarly across the baseline data, the
baseline data subsets and the follow-up data.
After linking the relevant follow-up data to the baseline data the change in HHS was
determined for each follow-up. The number of patients within the study was reduced
to 798, as all patients were required to have at least one follow-up with a HHS. The
distribution of the change in HHS for each follow-up showed that 96.6% of follow-up HHS













Figure 5.1: Side-by-side boxplot of the distribution of age for the baseline data (≤0) and
follow-up data (> 0). The baseline data is separated into those at the time of surgery
(= 0) and those in the year preceding surgery (< 0). Fainter points indicate a low density
of outliers while darker points indicate a high density of outliers (n = 897).
measurements are higher than the patient’s baseline. The mean change in HHS is 40.14,
which is relatively high as the HHS is only between 0 and 100, while the standard deviation
is 0.85. Of those patients who have recorded baseline measurements and follow-ups for
pain and function, almost all experience an improvement in HHS after surgery.
Figure 5.2 shows the distribution of the response variable, change in HHS. We see that
the majority of observations are an improvement from the baseline HHS measurement.
This again shows that there are relatively few observations that are worse than the baseline
HHS observation. The majority of observations are improvements of around 40-50 points.












Figure 5.2: Histogram of the change in Harris hip score (n = 897).
Figure 5.3 shows the density plots of the change in HHS (from baseline to follow-up)
separated into follow-up time brackets. The distribution of the change in HHS for follow-
ups that occurred within 12 months after surgery appears to have a lower peak and be
less left skewed than follow-ups that occurred beyond 12 months after surgery. Though
there is no stark difference between the first two and the last two time brackets we can
still see a slight increase in the peak change in HHS as time after surgery increases. This
suggests that patient pain and function is in general improving with time. The follow-up
times with a negative change in HHS are fairly evenly spread across the time brackets,
with the majority occurring within the first two years after surgery.
















Figure 5.3: Density plots of the change in HHS (from baseline to follow-up) separated
into follow-up time brackets (n = 897).
5.1 Mixed-Effects Model
To account for the repeated measurements of the change in HHS over time, application
of the class of statistical models known as mixed-effects models is appropriate [10]. These
models have been introduced in Chapter 4. Mixed-effects models can handle unbalanced
datasets, where each patient can have a varying number of follow-up measurements and
varying time between these follow-ups. Importantly, they account for the correlation
between repeated HHS measurements within a specific patient through the inclusion of
random effects.
Figure 5.4 shows a plot of the change in HHS trajectories over time for all patients
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with a baseline HHS measurement. As we would expect we see that patients often have
a varying number of follow-ups at non-consistent times. This again encourages the appli-
cation of mixed-effects models. We also see that there are few patients with a change in
HHS that is negative as most patients in this baseline sub-study experience improvements
in HHS after THR surgery.
A mixed-effects model was constructed with the change in HHS as the response vari-
able. In this case, we allow for separate average evolutions of change in HHS for each
patient, through random effects. We controlled for a collection of variables including, but
not limited to, baseline age, gender, follow-up time, place of residence and implant type.
On further analysis, there are no significant correlations between any of the predictor
variables. The strongest correlation is between weight and age and it is approximately
0.2. This model does not take into account any interactions but it includes a quadratic
term for follow-up time. Using the same stepwise process outlined in Chapter 4, predictor
variables that were significant (p-value < 0.05) were retained in the model. This model
was ultimately fit using restricted maximum likelihood (REML).
In the following analyses, the logit of the change in HHS is not used as it was in
previous analyses. This is because the assumption that the variance of the error terms is
constant was satisfied on the original HHS scale when we take the differences, which will
be discussed further.
The optimal random effects structure included only random intercepts. This was
in contrast to the previous mixed-effects model that also included random slopes. The
optimal model is written as,
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where ChangeInHHSij is the change in HHS of observation j from the baseline HHS
measurement for the i-th patient. The explanatory variables used in Equation 5.1 are
follow-up time and the quadratic term for follow-up time. The random effects, bi, are
normally distributed: N(0, d2). The errors, εij, are also normally distributed. Since
the optimal model is a random intercept model it allows for a random shift around the
intercept resulting in fitted lines that are parallel to the population fitted line.
Parameter Estimate SE p-value
Fixed Effect Intercept (mean change in HHS 34.65 0.81 <.0005
Estimates at 0 months)
Slope (months after surgery) 0.72 0.09 <.0005
Quadratic (months)2 -0.01 0.002 <.0005
Standard Deviation
Component of Within Patient Residual 11.66
Variance Estimates Between Patient Residual (int.) 14.19
Table 5.2: Model parameters for the optimal model of the change in HHS (Equation 5.1);
Number of observations: 779.
The results for the optimal model of the change in HHS are shown in Table 5.2. This
model suggests that follow-up time after surgery is strongly associated with the change in
HHS. An increase in follow-up time is associated with an increase in the change in HHS.
An increase in the quadratic term for follow-up time is associated with a decrease in the
change in HHS.
The variability of the intercept across patients has a standard deviation of 14.19, while
11.66 is the standard deviation of the variability within patients. The within patients
variability is smaller than the intercept variability, which suggests that the mixed-effects
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model is potentially accounting for the correlations within patient repeated measurements.















































Figure 5.5: Diagnostic plots for the random intercept model defined in Equation 5.1.
This includes scatterplots of the residuals against fitted values, and the residuals against
follow-up time and follow-up time2 (n = 779).
To check if the assumption of homogeneity was violated the following diagnostics were
explored. Figure 5.5 displays diagnostic plots for the random intercept model defined in
Equation 5.1. This includes scatterplots of the residuals against fitted values, and the
residuals against the continuous quantitative explanatory variables, follow-up time and
follow-up time2. Unlike previous models, this model does not fail to effectively predict
values about the upper bound of the HHS. This is due to the newly defined response
variable being change in HHS, instead of the transformed HHS. Figure 5.5 shows that the
assumption of homogeneity is satisfied, as there does not appear to be any clear trends
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Figure 5.6: Normal Q-Q plots of the conditional Pearson residuals for the model in Equa-
tion 5.1 (n = 779).
To further investigate the assumptions of the optimal mixed-effects model normal Q-Q
plots were explored. Figure 5.6 shows the normal Q-Q plot of the conditional Pearson
residuals. The normal Q-Q plots do show some small deviations from a linear trend at the
right upper tail. Nevertheless, these observations do not create a strong deviation from
the linear trend we expect to see in a normal Q-Q plot and therefore the assumption of
normality is reasonable.
We also look at the normal Q-Q plot of the predicted random effects, in this case the
random intercept. The effects are estimated using BLUPs (best linear unbiased predic-
tors), which were discussed in Section 4.2. The resulting Q-Q plot is shown in Figure
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Figure 5.7: The normal Q-Q plot of the predicted random intercepts for the model in
Equation 5.1 (n = 779).
5.7 and appears to be slightly curvilinear. However, this figure overall suggests that the
random effects are fairly normally distributed.
Since this model appears to satisfy the mixed-effects model assumptions we can now
look at it’s ability to make meaningful predictions. Though the optimal model within this
chapter only contains time variables we can still look at prediction. We are interested in
seeing if the predicted trajectories suggest that patient HHS generally improves with time
or not. We want to determine which patients are predicted to have an overall decrease
in HHS. Specifically the models ability to make predictions about a specific patient’s
change in HHS after surgery, in comparison to the previous mixed-effects model explored
in Chapter 4.
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Figure 5.8: Observed and predicted change in HHS for 16 random patients using the
optimal model (Equation 5.1). The blue points show the observed change in HHS for
each patient. The blue lines show the population level prediction and the pink dashed
lines show the individual level prediction.
Figure 5.8 shows the observed and predicted change in HHS for 16 randomly selected
patients. The x-axis is the follow-up time and the y-axis is the change in HHS. The
blue points show the observed change in HHS for that patient. The blue lines shows the
population level prediction and the pink dashed lines shows the individual level prediction,
both using the optimal model.
The predicted population means, shown in the Figure 5.8, increase very slightly over
time. Due to our assumed structure of the model, the population means are shifted for
individual patients by subject specific random intercepts. Therefore, we see that the
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intercepts of the individual profiles are different across subjects but the slope remains
the same. For some patients the predicted individual profiles deviate from the observed
measurements. For example, subjects 20627 shows a decrease in the observed values over
time, while the predicted individual patterns suggest an increase in the change in HHS
over time. Despite this, Figure 5.8 shows that individual level prediction can give an














Figure 5.9: Plot of the observed and predicted change in HHS for 10 randomly selected
patients last observation, given that we know the change in HHS of earlier observations.
The x-axis is the follow-up time and the y-axis is the change in HHS. The dotted lines show
the observed change in HHS trajectories. The smaller points are the observed change in
HHS. The larger points are the predicted change in HHS for the patient’s last observation.
The solid line shows the difference between the predicted and the observed change in HHS
for the patient’s last observation.
Figure 5.9 is a plot of the observed and predicted change in HHS for 10 randomly
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selected patients final observation, given that we know the change in HHS of their earlier
observations. The x-axis is the follow-up time and the y-axis is the change in HHS.
The dotted lines show the observed change in HHS trajectories. The smaller points are
the observed change in HHS. The larger points are the predicted change in HHS for the
patient’s last observation. The solid line shows the difference between the predicted and
the observed change in HHS for the patient’s last observation.
This shows that for most patients, within this figure, the predictions are fairly accurate,
as shown by the length of the solid lines. The predictions are particularly accurate for
patients whose HHS does not deviate greatly over time. This is a reflection of the use
of random intercepts. Since we do not include random slopes in this model and the only
explanatory variable within this model is follow-up time, it does not predict patients with
variable HHSs well. Due to the variability of many patient’s HHS trajectories within the
dataset this is a considerable limitation.
We can also predict a new patient’s HHS trajectory after surgery, based completely
on their baseline characteristics. Or in other words, we can predict the change in post-
operative patient pain and function based solely on follow-up time. To do this we look
at two methods. One method is to use the BLUPs, of the random effects, from other
patients within the estimation model frame to predict the HHS for a new patient. The
other method is comparing the prediction of a new patient using all possible BLUPs, of
the random effects, within the model. These methods are explained in more detail in
Section 4.2.
Figure 5.10 shows the predicted change in HHS trajectory. The change in HHS is on
the y-axis and the follow-up time is on the x-axis. In this case, we are using 12 random
observations to determine the random effect BLUPs for individual level prediction. The
solid black line denotes predicted individual change in HHS. The red line denotes the
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Figure 5.10: Plot of the predicted change in HHS trajectories against follow-up time using
the estimated parameters of 16 random patients. The solid black line denotes predicted
individual change in HHS. The red line denotes the predicted change in HHS trajectory
for an average patient. The dashed line indicates where the change in HHS is zero.
predicted change in HHS trajectory for an average patient. The dashed line indicates
where the change in HHS is zero. From Figure 5.10 we see that there is consistently
a predicted decrease in the change in HHS from 24 months to 48 months. Also we see
a predicted increase in the change in HHS between 0 and 24 months, with the fastest
improvement occurring between 0 and 12 months.
Similarly to Chapter 4 we can address the variability in predictions that occurs, de-
pending on how we select the appropriate estimators for the individual random effects,
we can look at the variation in prediction across all patients. This shows us how the
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Figure 5.11: Plot of the predicted change in HHS at 0, 3, 12, 24 and 48 months after
surgery. The x-axis is the patient ID. Each individual patient’s BLUPs for the random
effects is used but they are assumed to have the characteristics of an average patient. The
coloured smoother lines show the average change in HHS for patients at each follow-up
time. The solid black line indicates where the change in HHS is zero (n = 779).
Figure 5.11 displays the predicted change in HHS at 0, 3, 12, 24 and 48 months after
surgery. The x-axis is the patient ID. Each individual patient’s BLUPs for the random
effects is used but they are assumed to have the characteristics of an average patient. The
coloured smoother lines show the average change in HHS for patients at each follow-up
time. The solid black line indicates where the change in HHS is zero. Fortunately, this
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shows that the worst change in HHS is predicted to occur at 0 months. Likewise the best
predicted change in HHS appears to occur at 24 months. Unfortunately, it appears as
though the change in HHS lowers after 24 months, as the predicted change in HHS at 48
months is similar to 3 months after surgery. Again this could be because patients who
recover well from the surgery have less follow-up measurements after 24 months, creating
a bias in the predicted change in HHS at 48 months.
Figure 5.11 shows that the effect of the intercept on each patient simultaneously affects
our predicted value. This results in the multiple lines for predicted values across all
patients not being parallel, instead they resemble noise.
Throughout this chapter we have looked at determining an optimal mixed-effects
model for predicting the change in HHS after THR. It is clear that most patients are
predicted to see improvements in pain and function at 24 months after surgery. Neverthe-
less, we have seen that it is also optimal to have at least one HHS measurement to aid in
prediction, due to the effect of the intercept, though this is not always practical. Within
the dataset we also have access to patient survival information. This information could
help inform the predictions of HHS after surgery. Therefore, in the next chapter we will
explore survival analysis within the context of the THR dataset.
Chapter 6
Survival Analysis
The total hip replacement (THR) dataset that we received from the Royal Adelaide
Hospital (RAH) included, among patient and operation details, the survival outcomes for
THR patients. Though the primary focus of my research is analysing the longitudinal
pain and function data, survival analysis can still provide crucial insights. Specifically,
joint modelling of the survival and longitudinal outcomes has the potential to improve
postoperative patient pain and function prediction. This will be discussed further in
Chapter 7.
Firstly, it is important to study the survival times and the factors that influence them
before exploring joint modelling. This chapter includes preliminary survival analysis to
help us understand the nature of survival outcomes within this dataset, to prepare for
further modelling. Therefore, the ultimate aim is to pursue joint longitudinal and survival
modelling that will build on the survival analysis within this chapter.
Survival analysis is the study of survival times and the factors that influence them
[20]. In this case, we will use survival analysis to analyse the time until an event occurs,
the event being death. Within the dataset we have a variable that denotes a patient’s
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survival status (either alive or deceased) and another variable that states a patient’s date
of death (DOD), if relevant. Therefore, we can calculate the time between the operation











Figure 6.1: Histogram of the time between surgery and DOD for patients who are de-
ceased. The solid black line refers to the mean time between surgery and DOD, which is
9.5 years (n = 2280).
Figure 6.1 displays a histogram of the time between surgery and DOD for patients
who are deceased. The solid black line refers to the mean time between surgery and
DOD (9.5 years). The distribution appears to be right skewed with the majority of the
DODs occurring within 15 years after THR surgery. This is potentially indicative of
patients losing contact with the hospital as more time passes after surgery. More likely
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it is reflective of the older demographic that undergoes THR surgery and therefore only
live for around 15-20 years after surgery.
Patient Demographics Survived Deceased
n of patients 1244 1036
Mean (SD) age (yrs) 63.2 (12.7) 71.6 (9.8)
Mean (SD) weight (kgs) 81.1 (18.4) 75.6 (16.5)
Mean (SD) height (cms) 166.0 (12.9) 165.0 (11.2)
Female (n,%) 734 (59.0) 607 (58.6)
Male (n,%) 510 (41.0) 429 (41.4)
Diagnosis (n,%)
Osteoarthritis 920 (74.0) 814 (78.6)
AVN 112 (9.8) 70 (6.8)
Rheumatoid arthritis 27 (2.2) 30 (2.9)
Number of Comorbidities (n,%)
None 402 (32.3) 303 (29.2)
One 389 (31.2) 355 (34.3)
Two 258 (20.7) 239 (23.1)
Three 145 (11.7) 95 (9.2)
Four or more 50 (4.0) 44 (4.2)
Table 6.1: Summary of the distribution of demographic variables for patients separated
by survival status (n = 2280).
Table 6.1 shows a summary of the distribution of demographic variables for patients,
separated by survival status (alive or deceased). It is clear that there is large proportion
of patients within the dataset that are deceased (1036 patients). Therefore, we want to
determine if the profile of these patients is significantly different to the profile of patients
who are alive. We see that the mean age of deceased patients is greater than patients
who are alive and has a smaller standard deviation. There is also a larger proportion
of patients with one or two comorbidities within the subset of deceased patients when
compared to patients that are alive. Similarly, there is a higher proportion of patients
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with no comorbidities for patients that survived, compared to those that are deceased.
Interestingly, the mean weight of patients who survived is 81.1 kg, which is higher than the
mean weight of patients who are deceased (75.6 kg). Nevertheless, overall the distribution














Figure 6.2: Density plot of the age of THR patients separated by survival status. 1
indicates that a patient is alive and 2 indicates that a patient is deceased (n = 2280).
For variables that do show differences in distribution across the two survival groups
(alive and deceased) we can explore these differences further. Figure 6.2 shows the density
plots of the age of THR patients separated by survival status. 1 indicates that a patient
is alive and 2 indicates that a patient is deceased. The distribution of age for deceased
patients has a stronger left skew than for patients who are alive. This means that patients
who are deceased are more likely to have been older at the point of surgery. This is
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intuitive, as we would expect that patients who were younger at the point of surgery are
more likely to still be alive.
With this understanding of the survival outcomes within our dataset we can begin to
explore survival analysis. In our case, we are analysing the time between when a patient
has THR surgery and their DOD. But as we see in Table 6.1 some patients are still alive
at the end of the follow-up period, specifically the end of 2013. For these patients we
know that they survived up until the end of the follow-up period but we do not know how
much longer they survived after that time. These times are said to be right-censored, at
the end of 2013, which is the most common type of censoring within survival analysis [20].
Survival analysis methods depend on specifying a survival distribution. This can be
done through a survival function and a hazard function. The survival function is the
probability of surviving up until a time t and it can be written as,
S(t) = P (T > t), 0 < t <∞.
The hazard function is the instantaneous failure rate and is often used to define the
survival function. More specifically, the hazard function is the probability that, given a
patient is still alive at time t, the event, in this case death, will occur within the next
time point. This can be written as,
h(t) = lim
δ→0
P (t < T < t+ δ|T > t)
δ
There are numerous distributions that can be used to model survival data, making it
a parametric model. Nevertheless, it can be hard to determine which parametric model
is appropriate, or if there are any. Therefore, non-parametric methods are often used
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due to their flexibility. The most common of these is the Kaplan-Meier estimator derived
by Kaplan and Meier [15]. It is the product over the failure times of the conditional









where there are di failures among ri individuals in view at t. Therefore, the Kaplan-
Meier estimator tells us the estimated probability of a subject surviving beyond a certain
point, t [9].
Time since operations (yrs)

























Figure 6.3: Comparison of the Kaplan-Meier survival curves by gender; the dashed line
represents females and the solid line represents males. The grey areas are 95% confidence
intervals (n = 2280).
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Figure 6.3 is a comparison of the estimated Kaplan-Meier survival curves by gender.
The dashed line represents females and the solid line represents males. The grey areas are
95% confidence intervals. We can also determine the median lifetime, which for females
is 14 years and for males 11.7 years. Therefore, females are associated with a higher
survival probability. This is clear from Figure 6.3 as the dashed line lies above the solid
line up until about 24 years. At which point males are associated with a higher survival
probability.
Therefore, the Kaplan-Meier estimator helps us compare two survival distributions,
without assuming a parametric form. Nevertheless, we want to extend this to include
covariate information. A common method for doing this is the Cox proportional hazards
regression model. To help us define this model we let T ∗i be the true failure time for
the i-th individual and Ci be the censoring time. Then Ti = min(T
∗
i , Ci) represents the








where t > 0, wi is the covariates associated with the hazard, γ is the vector of regression
coefficients and h0(t) is the baseline hazard. This model investigates the effect of several
variables on a time-specified event taking place (in this case death, where censoring is an
incompletely observed death). This model assumes that the hazard ratio hi(t)
h0(t)
depends
only on covariates, whose value is fixed during follow-up [9]. Therefore, this model assumes
that the covariates are not time-dependent.
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A time-dependent explanatory variable, which is a variable that is not necessarily
constant through the whole study, may sometimes be of use within survival analysis. For
example, if one wishes to examine the link between age and second surgery (if they are
a bilateral patient) this would be complicated by the fact that study subjects move from
their first surgery to their second at different times. So second surgery can be introduced
in the statistical model as a time-dependent covariate. This is done by splitting each
study subject into two observations, one for their first surgery and one for their second
surgery [31].
Time-varying covariates can be added to Cox models by making wi a function of time,
wi(t). Therefore, the Cox proportional hazards model becomes,
hi(t) = h0(t) exp(γ
Twi(t)), t > 0.
There are two types of time-dependent covariates, called external or internal covariates.
An external covariate is a covariate which is not effected by an event occurring at an earlier
time. For example which season of the year we are in or any variable that is predetermined
at the start of the study (eg. treatment). In contrast internal covariates are all covariates
that are patient measurements, such as biomarkers [3]. For example, within the data we
have measurements relating to a patient’s Harris hip score (HHS) at different follow-up
times. This is an an internal time-varying covariate because in the future if that patient
undergoes a second THR their HHS will most likely be affected. Whereas the season of
the year with be unaffected, making it an external covariate. Time-dependent Cox models
are theoretically valid for external time-varying covariates. It is not always appropriate
when considering biomarkers, such as HHS, which will be discussed in Chapter 7. At this
point we are only looking at the survival outcomes in terms of the covariates, and the
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HHS is being ignored.






























Figure 6.4: Comparison of the number of comorbidities for time-dependent Cox propor-
tional hazards model with parameters: patient was on first surgery, had a revision, 67
years, had OA and was female (n = 2280).
Using a patient’s bilateral surgery as a time-dependent covariate we can explore the
difference in survival curves for patients that suffer from a varying number of comorbidi-
ties. Therefore, a simple time-dependent Cox proportional hazards model was fitted with
the covariates age, gender, osteoarthritis (OA) and the number of comorbidities that they
suffered from. The time-dependent covariate was whether a patient was on their first or
second surgery.
Figure 6.4 shows the results from fitting a time-dependent Cox proportional hazards
model plotted at different numbers of comorbidities. The variables are set to the following
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values: patient was on first surgery, 67 years, had OA and was female. This figure indicates
that suffering from more comorbidities is associated with a lower survival probability.
Patients with no comorbidities are associated with a higher survival probability than
patients with any other number of comorbidities.
Using this framework for the modelling of survival outcomes we can explore joint mod-
elling. This will rely on the use of the Cox proportional hazards model. Likewise, the
longitudinal outcomes analysis presented in Chapter 4 will also be crucial in implementing
joint modelling. This is explored with the hypothesis that the inclusion of survival out-
comes, jointly modelled with the longitudinal outcomes, will help inform the prediction
of pain and function after surgery.
Chapter 7
Joint Modelling
In medical research, longitudinal and time-to-event information are often collected to-
gether. For example, in the total hip replacement (THR) dataset, patients who undergo a
THR have follow-up Harris hip score (HHS) measurements and during that period death
or revision can occur. Another example is a prostate cancer study, where death and
metastasis can occur during the follow-up period [25]. While it is possible to analyse the
time-to-event and longitudinal outcomes separately, this is not always adequate. There
are situations were addressing both outcomes in one analysis is optimal. Sometimes it is
more appropriate to address both of these outcomes within a joint model.
7.1 Joint Model
Joint modelling may be useful for a few reasons. Firstly, if we are interested in the
association between the longitudinal and survival outcomes. For example, the association
between the HHS measurements and the time until death. Another reason may be to
include the effect of the time-dependent covariate measured with error in survival analysis.
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This means we can include the effect of the HHS, measured with error, in the survival
sub-model. Joint modelling can also be used to account for possible outcome dependant
drop out in a longitudinal study. Therefore, it can account for the possible dependancy
between HHS and survival status [5].
In previous chapters we have addressed both the time-to-event and longitudinal out-
comes separately. In this chapter we will address the joint modelling of these outcomes.
Joint models are a combination of both mixed-effects models and Cox models. Therefore,
what follows is a brief reminder of mixed-effects models and Cox models, followed by the
joint modelling framework.
7.1.1 Mixed-Effects Model
Mixed-effects models, addressed in more depth in Chapter 4, allow for random intercepts
and slopes for each patient. This allows each patient within the study to have their own
evolution in HHS over time. We let yi(t) denote the follow-up measurements for the i-th
subject (i=1,. . .,n) at time t. These measurements are obtained at time points tij, where
j=1,. . ., ni. Therefore, a general mixed-effects model can be written as
yi(t) = xi(t)
Tβ + zi(t)
T bi + εi(t),
bi ∼ N(0, D),
εi ∼ N(0, σ2),
where β is the regression coefficients of the design matrix for the fixed effects, xTi ,
and zTi is the design matrix for the random effects, bi. D is the covariance matrix of the
random effects, εij(t) are the error terms, with variance σ
2. The fixed effects relate to the
7.1. Joint Model 121
population effects while the random effects refer to the subject specific effects.
The parameters for this model are estimated by maximum or restricted maximum
likelihood (ML and REML). The random effects are predicted by their conditional expec-
tations given the data, this minimises the mean square prediction error.
7.1.2 Cox Model
Cox models, addressed in Chapter 6, use covariate information to determine the hazard
of each subject. Let T ∗i be the true failure time for the i-th individual and Ci be the
censoring time. Then Ti = min(T
∗
i , Ci) represents the observed failure time for the i-th
patient. The Cox proportional hazards regression model is written as
hi(t) = lim
dt→0
Pr(t ≤ T ∗ < t+ dt|T ∗ ≥ t)
dt
= h0(t) exp(γ
Twi), t > 0,
where wi is the covariates associated with the hazard, γ is the vector of regression
coefficients and h0(t) is the baseline hazard. This model assumes that the hazard ratio
hi(t)
h0(t)
depends only on covariates, whose value is fixed during follow-up. Therefore, excluding
time-varying covariates.
As discussed previously, time-varying covariates can be added to Cox models by mak-
ing wi a function of time, wi(t). Time-dependent Cox models are theoretically valid for
external time-varying covariates. It is not always appropriate when considering biomark-
ers, such as HHS. This is due to an expectation that biomarkers will evolve relatively
smoothly over time, which the time-dependent Cox model does not take into account.
This creates bias in the estimated effect of the biomarker. This further motivates the use
of joint modelling, as HHS is not an appropriate time-dependent covariate within a Cox
model. In contrast, the HHS is more appropriately addressed in joint modelling.
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As discussed earlier, the idea behind the joint model is to combine the continuous time-
to-dropout process with a mixed-effects model for the longitudinal outcome. A commonly




T bi + εi(t)
hi(t) = h0(t) exp
[
γTwi + α{xi(t)Tβ + zi(t)T bi}
]
, t > 0,
(7.1)
where α is the effect of the underlying longitudinal outcome to the risk for an event.
Therefore, α is of particular interest as it describes how the covariates affect the relative
hazard. This model assumes that the risk associated with the outcome dependent dropout
is related to the unobserved value of the longitudinal outcome. It also assumes that
the random effects account for the correlation between repeated measures and also the
association between the longitudinal and survival processes [28]. This survival sub-model
is more appropriate than a Cox model with a time-varying covariate as it takes into
account the idea that HHS evolves smoothly over time. It is fair to assume that in reality
a patient’s pain and function would smoothly increase or decrease between visits, unless
there was a trauma incident. In contrast, the time-dependent Cox model assumes that
the HHS is constant between visits.
An important part of joint modelling is that repeated measurements and survival data
are modelled simultaneously. By using the model’s assumptions it predicts the values of
yi(t) at all times and therefore estimates the association between the longitudinal and
survival processes, α, while making allowance for the measurement error in the observed
response [5].
The parameters of this joint model are estimated through maximum likelihood, and
random effects are predicted by their conditional expectations given the data. There are
























Figure 7.1: Graphical representation of joint models. Top: The hazard function for
survival status. Bottom: the dashed line describes a time-dependent covariate as used in
the time-dependent Cox model, and the solid line the mixed-effects model reconstruction
of the transformed HHS trajectory.
different methods used to maximise the likelihood, one of which will be addressed later
in this chapter.
The joint model outlined above uses mixed-effects modelling to estimate biomarkers
that evolve smoothly over time. It then uses these estimated biomarkers within a time-
dependent Cox model in the place of the observed biomarkers. Figure 7.1 displays this
idea as the bottom panel compares the estimated evolution of the transformed HHS using
mixed-effects models (solid line) and compares it to the observed transformed HHS as a
time-dependent covariate (dashed line).
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This model is often used in the context of improving estimation of survival outcomes.
Our study is ultimately concerned with how to account for outcome dependent drop out,
and it’s effect on the longitudinal outcome. This is because our primary concern is still
estimating postoperative patient pain and function. Nevertheless, this commonly used
joint model framework is a suitable foundation to begin joint modelling the HHS and
survival outcomes.
With joint modelling, as with all modelling, comes limitations. The main disadvantage
is computation cost and effort and the relatively little software in place to compute these
models [5]. This problem is less significant when dealing with smaller datasets with less
observations and fewer random effects. There are packages, such as JM [27], that are
being developed within Rstudio that are able to compute some of these models. In this
chapter we will use this package to perform joint modelling.
7.2 Joint Model Sub-study
Now we explore joint modelling within the context of our THR dataset. Firstly, we
created a subset of patients with a valid survival status (whether they were deceased)
and a valid date of death, if they were deceased. Furthermore, these patients all needed
at least one valid follow-up HHS measurement. After these restrictions the number of
patients in the sub-study was 1850. Using t-tests and comparing proportions we could
determine that the distribution of gender, age and survival status was approximately the
same in the sub-study as in the whole dataset (2280 patients). The response variable,
HHS, is transformed using the logit transformation to better satisfy the assumptions of
the model, as discussed in Chapter 4.
The longitudinal sub-model of the joint model is a random intercept and slope model,
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as this was the optimal random effects structure for the mixed-effects model explored in
Chapter 4. Each patient has their own random intercept and random slope. Therefore,
we assume there is a relationship between HHS and follow-up time that is different for
each patient.
This joint model was fit using the JM package in R [26]. This uses maximum likelihood
but requires specification regarding the type of sub-model to be fitted and the method of
numerical integration. The type of sub-model to be fitted is a relative risk model with a
piecewise-constant baseline risk function. The relative risk model is in the form
hi(t|Mi(t), wi) = h0(t) exp{γTwi + αmi(t)},
where Mi(t) = mi(u), 0 ≤ u < t is the history of the true unobserved longitudinal
process up to time point t, h0(.) is the baseline risk function and wi is the vector of
baseline covariates with a vector of regression coefficients γ [27]. The piecewise-constant




ξqI(vq−1 < t ≤ vq),
where 0 = v0 < v1 < . . . < vQ is a split of the time scale, with vQ being larger than
the maximum observed time, and ξq is the value of the hazard in the interval (vq−1, vq].
To use maximum likelihood estimation we need to maximise the log-likelihood of the
joint distribution. To define the log-likelihood of the joint distribution we define the
time-to-event and longitudinal outcomes as Ti, δi, yi and recall the assumption that the
random effects, bi, underlie both the longitudinal and survival process. This creates
conditional independence as the random effects account for both the association between
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the longitudinal and event outcomes and the correlation between repeated measurements
in the longitudinal process. Since conditional independence implies that
p(A,B|C) = p(A|C)p(B|C).
In the context of the probability density function for the joint model we get










T is a vector of parameters and the event time outcome, longi-
tudinal outcome and random effects covariance matrix respectively. The variable yi is the
vector of longitudinal responses of the i-th subject. Therefore, using these assumptions
we can derive the joint log-likelihood contribution for the i-th subject.
log p(Ti, δi, yi;α) = log
∫












This is the product of the the likelihood of the survival, the univariate normal density
for the longitudinal response and the multivariate normal density for random effects,
respectively. This is computationally difficult to solve because the integral, with respect
to the random effects and survival function, does not have an analytical solution (except
in a few cases) [27]. To solve this integral one approximation that can be used is the
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where n is the number of sample points, xi are the roots of the Hermite polynomial





. There are other methods of approximation
that can be used such as the Laplace approximation [29] though in this case it is not as
appropriate as we do not have high-dimensional random effects structures.
Variable Estimate SE p-value HR
logit(HHS) -0.12 0.002 <0.001 0.891
Baseline age (years) 0.05 0.047 <0.001 1.053
Gender 0.36 0.018 <0.001 1.426
Table 7.1: Results for the Cox model, where HHS is only the last observed HHS measure-
ment (n = 1850).
To illustrate the advantage of using a joint modelling approach, first a Cox model
was fitted using only the last observed HHS measurement, baseline age and gender as
predictors of survival status. The results of this model are shown in Table 7.1. Then a
joint model was specified using the framework previously defined (Equation 8.1). The
longitudinal sub-model included the predictor variables baseline age, gender, and follow-
up time. Moreover, it included random intercepts and slopes, due to the random effects
structure of the optimal model in Chapter 4. Though in further exploration we could
include different baseline covariates for the Cox model and mixed-effects model, depending
on what is of interest. At this stage we simply kept the covariates the same across both
models.
Results from this joint model are shown in Table 7.2 and compared to the results of
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Variable Estimate SE p-value
Longitudinal sub-model
Intercept 1.9841 0.1665 <0.001
Baseline age (years) -0.0123 0.0024 <0.001
Follow-up time 0.0107 0.0010 <0.001
(Follow-up time)2 -0.0001 <0.001 <0.001
Gender 0.3581 0.0572 <0.001
Variable Estimate SE p-value HR
Survival sub-model
logit(HHS) -0.3117 0.0480 <0.001 0.7322
Baseline age (years) 0.0776 0.0045 <0.001 1.0807
Gender 0.5613 0.0784 <0.001 1.7530
Table 7.2: Results for the joint modelling analysis of the THR dataset. For both sub-
models, estimated parameters, standard errors (SE) and p-values are reported (n = 1850).
the Cox model shown in Table 7.1. Both the parameter estimates and the p-values are
recorded. In the Cox model for mortality (Table 7.1), older patient age, lower transformed
HHS and gender are associated with an increased death hazard. Using the joint model for
mortality (Table 7.2), the same predictor variables remain significantly associated with an
increased death hazard. Nevertheless, we see that in the joint model a higher coefficient
is estimated for gender when compared to the Cox model. This implies that the joint
model estimates being male has a larger effect on a patient’s survival probability than
in the Cox model. By using repeated HHS measurements instead of only the last HHS
measurement the model outcomes can change and different conclusions can be drawn.
Therefore, accounting for the idea that pain and function are not independent from death,
through joint modelling, may allow for more appropriate insights into patient pain and
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function after THR.
We again note that this particular joint modelling framework is motivated by the time-
to-event point of view. It incorporates the HHS as a time-dependent covariate measured
with error in a survival model. Nevertheless, incorporating the association between the
survival and longitudinal outcomes still gives us greater insight into the trajectory of
patient pain and function after THR. This is crucial as we are more motivated by how
best to incorporate the time-to-event information into a longitudinal analysis. Therefore,
this joint modelling framework is still informative and will be the framework explored
further in this chapter. Though a different approach could be explored in future to
further focus on the behaviour of the HHS after surgery.
7.2.1 Diagnostics
To assess the appropriateness of the joint model (Table 7.2) we need to explore the
diagnostics. Firstly we look at the residuals for the longitudinal sub-model of the joint
model. Due to the nature of the sub-model, it has both subject specific residuals and
population averaged residuals. The first of these aims to validate the homoscedasticity




i (t)β + z
T
i (t)bi + εi,
bi ∼ N(0, D), εi ∼ N(0, σ2),
with residuals
rysi (t) = {yi(t)− xTi (t)β̂ − zTi (t)b̂i}
that predict the conditional errors εi(t). In contrast, the marginal residuals investigate
misspecification of the mean structure xTi (t)β and validate the assumptions for the within-
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∗
i ,
ε∗i ∼ N(0, ZiDZTi + σ2Ini),
with residuals
rysmi = yi −Xiβ̂
that predict the marginal error [28]. Both the subject-specific and the marginal residuals
are used to validate the assumptions of the longitudinal sub-model within the joint model.
Figure 7.2 shows the subject specific residuals versus the fitted values, the Q-Q plot
of the subject specific residuals, and the marginal survival and cumulative risk functions
for the event process. The residuals versus fitted plot appears to validate the model’s
assumptions due to the random scatter of the residuals and their centering around zero.
The deviations that form a sharp line in the top right of this plot are again HHS obser-
vations that are 100. Likewise, the normal Q-Q plot displays this poor behaviour at the
boundary of the HHS with the nonlinearity of the upper tail. Overall, without the poor
behaviour at the boundary of the HHS, these residuals support the model’s assumptions.
Figure 7.3 shows the marginal standardised residuals versus fitted values for the lon-
gitudinal outcome of the THR dataset, which is the transformed HHS. There is a fitted
loess curve that suggests that there are more positive residuals for smaller fitted values.
Likewise, there appears to be more negative residuals for larger fitted values. This may
be due to nonrandom dropout in the HHS measurements caused by death. This implies
that patients who have a lower HHS may have a higher death rate. This may be because
the residuals of the smaller fitted values are based on patients with, mostly, good HHSs
(> 70), creating a systematic trend in the marginal residuals.
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Figure 7.2: Diagnostic plots for the joint model fitted to the THR dataset. Included are
the subject specific residuals versus the fitted values, the Q-Q plot of the subject specific
residuals, and the marginal survival and cumulative risk functions for the event process
(n = 1850).
The residuals for the survival sub-model also need to be explored. Martingale residuals
are a standard type of residual used to address survival models. This residual is the
difference between the observed number of events, in this case death, for the i-th patient
until time t, and the expected number of events, using the fitted model. Therefore, it is
similar to the residual definitions used previously, where the THR data is defined by the
model and an error term.
Figure 7.4 shows the martingale residuals versus the subject specific fitted values of
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Figure 7.3: Marginal standardised residuals versus fitted values for the longitudinal out-
come of the THR dataset (n = 1850).
the longitudinal outcome for the THR dataset. The grey solid line denotes the fit of the
loess smoother. It is clear that for smaller fitted values of the longitudinal outcome the
loess smoother is further from zero. To further investigate this potential systematic trend
we condition on gender and then inspect the martingale residuals.
Figure 7.5 shows the martingale residuals versus the subject specific fitted values of
the longitudinal outcome separated by gender for the THR dataset. The grey solid lines
denotes the fit of the loess smoother. There still appears to be deviations in the loess
smoother from zero but these appear to be consistent across both genders. Therefore,
this deviation may be reflective of poor model behaviour for patient’s with low fitted
HHS values, potentially due to limited data in this area.
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Figure 7.4: Martingale residuals versus the subject specific fitted values of the longitudinal
outcome for the THR dataset. The grey solid line denotes the fit of the loess smoother
(n = 1850).
Another type of residual that can be used to help inform us about the survival sub-
model is the Cox-Snell residuals. These residuals are the estimated cumulative risk func-
tion evaluation for each patient at the observed event time Ti. Therefore, the Kaplan-
Meier estimate of the survival function of the Cox-Snell residuals is plotted [28].
Figure 7.6 shows the Cox-Snell residuals for the survival sub-model. The black solid
line denotes the Kaplan-Meier estimate of the survival function of the residuals (with the
dashed lines corresponding to the 95% point-wise confidence intervals), and the grey solid
line, the survival function of the unit exponential distribution. We compare the Kaplan-
Meier estimate with the survival function of the unit exponential distribution as this is
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Figure 7.5: Martingale residuals versus the subject specific fitted values of the longitudinal
outcome separated by gender for the THR dataset. The grey solid lines denotes the fit of
the loess smoother (n = 1850).
the expected asymptotic distribution. It is clear that there are some strong differences
between these two lines. This is particularly evident for smaller residuals. This is not
ideal as we expect the survival function estimate to be close to the unit exponential
distribution.
The diagnostics have shown that this model is potentially ill-specified due to systematic
behaviour in the residuals. This may be because the joint model explored in this section
only includes the predictors age, gender and follow-up time. In contrast, the optimal
mixed-effects model in Chapter 4 includes more predictor variables. Therefore, we now
consider including more variables to explore if this improves the model fit.
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Figure 7.6: Cox-Snell residuals for the survival sub-model. The black solid line denotes
the Kaplan-Meier estimate of the survival function of the residuals (with the dashed lines
corresponding to the 95% point-wise confidence intervals), and the grey solid line, the
survival function of the unit exponential distribution (n = 1850).
7.3 Joint Model with New Longitudinal Sub-model
The previous joint model showed some limitations when analysing the diagnostics. As a
result, in this section, we introduce more predictor variables into the joint model (Equa-
tion 8.1). The variables that we include are those that were significant within the optimal
mixed-effects model presented in Chapter 4. Therefore, we will look at including weight,
AVN status, number of comorbidities and smoking status, along with the variables ad-
dressed in the previous analysis.
These variables were included and a joint model was formulated using the same process
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outlined in the previous section. We note that the new predictor variables were only
included in the longitudinal sub-model. The survival sub-model remained the same as
the previous joint model.
Table 7.3 shows the results of this joint model, which includes more variables in the
longitudinal sub-model. It is clear that the variables that have been added are all signifi-
cant within the model. Similarly to previous analysis, this table indicates that having a
heavier weight is associated with a decrease in HHS. Likewise, suffering from AVN is as-
sociated with a decrease in HHS when compared to not suffering from AVN. Interestingly,
in this model suffering from more comorbidities is associated with a greater decrease in
HHS. This was not the case for the separate mixed-effects model. Therefore, having four
or more comorbidities is associated with a lower HHS than having three comorbidities.
For the variable place of residence, patients who have external support are again associ-
ated with a decrease in HHS when compared to patients who live independently. Lastly,
patients who smoke moderately are associated with a decrease in HHS when compared to
patients who do not smoke at all.
Table 7.3 also shows the hazard ratio (HR), which is the ratio of the hazard rates
relating to the two levels of the explanatory variables. For example, males appear to
die at approximately twice the rate per unit time as females, as the HR is almost 2.
Therefore, a higher HR indicates a higher hazard of death. We note that the HR is a
relative measure of effect and does not inform us about absolute risk [22]. Interestingly
age has a HR of approximately one. This indicates that an increase in age is associated
with only a slightly higher hazard of death.
Table 7.3 also shows that the association between the transformed HHS and the sur-
vival outcome is significant and negative. This means that having a higher HHS is asso-
ciated with a higher survival probability, which is as expected. Patients who experience
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Variable Estimate SE p-value
Longitudinal sub-model
Intercept 2.92 0.36 <0.001
Baseline age (years) -0.01 0.004 <0.001
Follow-up time 0.02 0.002 <0.001
(Follow-up time)2 -0.0002 <0.001 <0.001
Gender 0.43 0.09 <0.001
Weight -0.007 0.002 0.002
AVN -0.47 0.14 0.001
Number of Comorbidities
One -0.02 0.11 0.83
Two -0.26 0.12 0.03
Three -0.41 0.14 0.003
Four or more -0.43 0.18 0.02
Place of Residence
Home alone & external support -0.40 0.16 0.01
Home with others & independent -0.05 0.10 0.60
Home with others & support -0.54 0.12 <0.001
Other -0.54 0.29 0.06
Smoker (non-smoker)
Moderate -0.48 0.13 0.0003
Heavy 0.17 0.29 0.55
Variable Estimate SE p-value HR
Survival sub-model
logit(HHS) -0.35 0.10 <0.001 0.71
Baseline age (years) 0.06 0.008 <0.001 1.07
Gender 0.66 0.14 <0.001 1.93
Table 7.3: Results of the joint model, which includes more variables in the longitudinal
sub-model. For both sub-models, estimated parameters, standard errors (SE) and p-values
are reported (n = 1850).
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less pain and greater function are more likely to not only be younger, but also to suffer
from less conditions that will increase their risk of death.
7.3.1 Diagnostics












































































Figure 7.7: Diagnostic plots for the joint model fitted to the THR dataset. Included are
the subject specific residuals versus the fitted values, the Q-Q plot of the subject specific
residuals, and the marginal survival and cumulative risk functions for the event process
(n = 1850).
It is again important to explore the diagnostics of this model. Particularly in com-
parison to the previous model to identify if the joint model with more predictor variables
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within the longitudinal sub-model is more appropriate. Figure 7.7 shows the diagnostic
plots for the joint model fitted to the THR dataset. The residuals versus fitted plot shows
residuals that are slightly more centered around zero when compared to the residuals in
the previous model (see Figure 7.2). The normal Q-Q plot shows no significant difference
to the previous model.

















Figure 7.8: Marginal standardised residuals versus fitted values for the longitudinal out-
come of the THR dataset (n = 1850).
Figure 7.8 shows the marginal standardised residuals versus fitted values for the lon-
gitudinal outcome of the THR dataset. There is a fitted loess curve that suggests that
there are more positive residuals for smaller fitted values. Nevertheless, in comparison
to the marginal residuals from the previous joint model (see Figure 7.3) this trend is
less significant. It is also clear that the lower bound of the fitted values has increased
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in comparison to the previous model. Therefore, the inclusion of more variables, which
means more patients are ignored due to missingness, may have disregarded some patients
with particularly low HHS measurements. Nevertheless, the systematic trend within the
marginal residuals that is shown in Figure 7.8 is fairly small.




















Figure 7.9: Martingale residuals versus the subject specific fitted values of the longitudinal
outcome for the THR dataset. The grey solid line denotes the fit of the loess smoother
(n = 1850).
Next we explore the diagnostics of the survival sub-model. Here we see that this
joint model is more appropriate than the previous joint model. Figure 7.9 displays the
martingale residuals versus the subject specific fitted values of the longitudinal outcome
for the THR dataset. The grey solid line denotes the fit of the loess smoother. For
smaller fitted values of the longitudinal outcome the loess smoother is only slightly further
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from zero. In comparison to the previous model (Figure 7.4) the deviation from zero is
significantly smaller.
















−2 0 2 4 6
F
−2 0 2 4 6
M
Figure 7.10: Martingale residuals versus the subject specific fitted values of the longitu-
dinal outcome separated by gender for the THR dataset. The grey solid lines denotes the
fit of the loess smoother (n = 1850).
Figure 7.10 displays the martingale residuals versus the subject specific fitted values of
the longitudinal outcome separated by gender for the THR dataset. The grey solid lines
denotes the fit of the loess smoother. There appears to be only minor deviations in the
loess smoother from zero but these appear to be similar deviations across both genders.
Therefore, the systematic trend that was more evident within the previous model has
definitely diminished in this joint model.
The Cox-Snell residuals can also be explored to further analyse the survival sub-model
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Figure 7.11: Cox-Snell residuals for the survival sub-model. The black solid line denotes
the Kaplan-Meier estimate of the survival function of the residuals (with the dashed lines
corresponding to the 95% pointwise confidence intervals), and the grey solid line, the
survival function of the unit exponential distribution (n = 1850).
residuals. Figure 7.11 shows the Cox-Snell residuals for the survival sub-model. The black
solid line denotes the Kaplan-Meier estimate of the survival function of the residuals (with
the dashed lines corresponding to the 95% pointwise confidence intervals), and the grey
solid line, the survival function of the unit exponential distribution.
When comparing the Kaplan-Meier estimate with the survival function of the unit
exponential distribution it is clear that there are differences between these two lines,
particularly for smaller residuals. Though we would expect the survival function estimate
to be close to the unit exponential distribution, it is still a definite improvement on the
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fit of the previous joint model. When comparing Figures 7.6 and 7.11 it is clear that the
second joint model has a Kaplan-Meier estimate that sits closer to the survival function
of the unit exponential distribution.
The diagnostics show that the addition of predictor variables, from the optimal mixed-
effects model in Chapter 4, into the longitudinal sub-model of the joint model improves
the model. Therefore, in future it would be beneficial to look further into determining
an optimal survival sub-model that potentially includes more predictor variables. At this
stage we do not explore this.
This section shows that our second joint model fits the data better than our initial joint
model. Specifying differently the association structure in the joint model is not considered
in this here but could also be a potential way of improving the model. Nevertheless,
we can explore how to approach prediction for this joint model. We can discuss these
predictions within the context of the predictions made using the mixed-effects model
defined in Chapter 4. These predictions will be compared within the context of the
original research question, which is how can we predict postoperative patient pain and
function based on preoperative factors, such as age and gender.
7.3.2 Prediction
Joint models can be used to obtain individual patient level predictions across both lon-
gitudinal and survival outcomes. Particularly of interest to us is the dynamic prediction
of the longitudinal outcomes, the HHS measurements. This is because our aim is to
develop a model that can predict postoperative patient pain and function based on pre-
operative factors. Nevertheless, later in this section we will also address dynamic survival
probability prediction alongside the longitudinal predictions.
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In the case of longitudinal outcomes the expected HHS measurement at time u > t,
given the observed HHS up until that point, yi(t){yi(s), 0 ≤ s < t}, can be written as
wi(u|t) = E{yi(u)|T ∗i > t, Yi(t), Dn; θ8}, u > t. (7.2)
This is dynamic as with time more information is used to calculated the new prediction.
Therefore, more HHS measurements are used to inform predictions made at later times
after surgery. This estimation is completed using a Monte Carlo simulation scheme, which
will be explored further in the context of survival probabilities later in this section [28].
This method of estimation will be used to determine predicted longitudinal outcomes
in the results that follow. Initially we will compare prediction methods used in Chapter
4 that do not involve dynamic prediction. Then, later in this section, dynamic prediction
will be explored.
Firstly, we use a similar process as used in Section 4.2.2 (Figure 4.11). This method
selects a random patient and removes their last observation from the estimation model
frame and then attempts to predict the HHS observation at that time. Therefore, this
compares how well the model can predict the final HHS measurement given that it has a
patient’s previous measurements.
Figure 7.12 shows a plot of the observed against the predicted HHS for 500 patient’s
last HHS observation. We can see that for patients who have a low HHS observation the
model appears to predict values that are higher than the observed values. In contrast, for
patients who have a higher HHS observation the model appears to predict values that are
lower than the observed value. Nevertheless, for patients whose HHS is within the area
of highest density the predictions are fairly accurate. Overall, there is a systematic trend
that exists within the prediction of the longitudinal outcomes. This trend was visible





















Figure 7.12: Plot of the observed against the predicted HHS for the last observation of
500 patient’s last HHS observation.
within the longitudinal sub-model residuals and is further confirmed by this analysis.
This can be compared to a similar prediction plot relating to the optimal mixed-effects
model in Chapter 4 (Figure 4.15). The predictions made by this joint model are more
accurate as they sit closer to the linear line. Although, with this accuracy a systematic
trend becomes clear.
We can also look closer at a subset of patients. Figure 7.13 shows a plot of the observed
and predicted HHS measurements for 10 randomly selected patients last observation, given
that we know the HHS measurements of earlier observations. The x-axis is the follow-up
time and the y-axis is the transformed HHS. The dotted lines show the observed patient
HHS trajectories. The smaller points are the observed patient HHS measurements. The





















Figure 7.13: Plot of the observed and predicted HHS measurements for 10 randomly se-
lected patients last observation, given that we know the HHS measurements of earlier
observations. The x-axis is the follow-up time and the y-axis is the transformed HHS.
The dotted lines show the observed patient HHS trajectories. The smaller points are the
observed patient HHS measurements. The larger points are the predicted HHS measure-
ments for the patient’s last observation. The solid line shows the difference between the
predicted and the observed HHS measurements for the patient’s last observation.
larger points are the predicted HHS measurements for the patient’s last observation. The
solid line shows the difference between the predicted and the observed HHS measurements
for the patient’s last observation. This supports what is shown in Figure 7.12 that lower
HHS measurements are consistently over predicted and higher HHS measurements appear
to be under predicted. Those HHS measurements that lie in the middle are the most
accurately predicted measurements.
We now illustrate the dynamic nature of longitudinal predictions. To do this we take






















Follow−up time: 6.7 Follow−up time: 15.4
0 50 100







Figure 7.14: Dynamic predictions of the longitudinal responses for Patient 10056. In
each panel the dotted vertical line indicates the time point of the last observed HHS
measurement. The solid line denotes that fitted longitudinal trajectory prior to the last
visit, and the dashed line represents the predicted longitudinal trajectory. The grey areas
denote the 95% pointwise confidence intervals.
one patient and show how their HHS predictions update over time. Figure 7.14 shows
dynamic predictions of the longitudinal responses for Patient 10056. In each panel the
dotted vertical line indicates the time point of the last observed HHS measurement. The
solid line denotes that fitted longitudinal trajectory prior to the last visit, and the dashed
line represents the predicted longitudinal trajectory. The grey areas denote the 95%
pointwise confidence intervals.
We see that at follow-up time three the predicted trajectory shows a sharper eventual
descent than at later follow-up times. This is because the patient’s HHS measurements
148 Chapter 7. Joint Modelling
did not drop significantly over time, therefore the prediction updated accordingly. As we
would expect the width of the confidence interval is larger at greater times as a prediction
made near the time of the last measurement is much more reliable. These confidence
intervals are not symmetric as they are not based on an asymptotic normality of ŵi(u|t)
[28]. This form of prediction is useful within personalised medicine as we are constantly
receiving new information on a patient. Therefore, the best predictions occur when a
patient, who is already in the system, is having their biomarkers measured regularly.
We can also examine the dynamic survival probabilities prediction alongside the lon-
gitudinal predictions. Therefore, we look at predicting a patient’s survival probability at
a certain time after surgery. To do this we let Dn = {Ti, δi, yi; i = 1, . . . , n} be a random
sample that the joint model is fitted in. We look at predicting the survival probabilities of
a new patient with HHS measurements Yi(t) = {yi(s); 0 ≤ s < t} and baseline covariates
wi. Therefore, the conditional probability of surviving time u > t given survival up to t
can be written as
πi(u|t) = Pr(T ∗i ≥ u|T ∗i > t, Yi(t), wi, Dn; θ∗), t > 0 (7.3)
where θ∗ are the true parameters. We note that this conditional probability again has
a dynamic nature because as time increases the parameter t increases and the predictions
are updated accordingly [28].
When estimating the individual level conditional survival probabilities we use the
conditional independence assumption. The conditional independence assumption can be
written as
p(Ti, δi, yi|bi; θ) = p(Ti, δi|bi; θ)p(yi|bi; θ),
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as shown in Section 7.2. Applying the above assumption to Equation 7.3 we get
Pr(T ∗i ≥ u|T ∗i > t, Yi(t), wi, Dn; θ)
=
∫
Pr(T ∗i ≥ u|T ∗i > t, bi; θ)p(bi|T ∗i > t, Yi(t), wi, Dn : θ)dbi
=
∫
Si{u|Mi(u, bi, θ); θ}
Si{t|Mi(t, bi, θ); θ}
p(bi|T ∗i > t, Yi(t), wi, Dn : θ)dbi, (7.4)
where Si(.) is the survival function and Mi(.) is the longitudinal history of the i-th
patient. We note that this equation does have redundancy but it was used in this form
to be consistent with the text.
Using Equation 7.4 and the posterior expectation of Equation 7.3 we can apply a
Monte Carlo simulation scheme to estimate πi(u|t) [28]. After performing this simulation
scheme the realisations of {πli(u|t), l = 1, . . . , L} can be used to derive point estimates of
πi(u|t), such as
π̂i(u|t) = median{πli(u|t), l = 1, . . . , L}.
This method of estimation will be used to determine predicted survival probabilities
in the results that follow. We note that in this case we will again be looking at prediction
for patients that already exist within the estimation model frame.
Figure 7.15 shows dynamic survival probabilities for Patient 10056 from the THR
dataset during follow-up. The vertical dotted lines represent the time point of the last
HHS measurement. Left of the vertical line, the fitted longitudinal trajectory is depicted.
Right of the vertical line, the solid line represents the median estimator for πi(u|t), and
the dashed lines the corresponding 95% confidence intervals. This prediction assumes
that the last time point that the patient was still alive was when they last had a HHS
measurement recorded. Therefore, for all previous time points u < t, πi(u|t) = 1.
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Figure 7.15: Dynamic survival probabilities for Patient 10056 from the THR dataset
during follow-up. The vertical dotted lines represent the time point of the last HHS
measurement. Left of the vertical line, the fitted longitudinal trajectory is depicted.
Right of the vertical line, the solid line represents the median estimator for πi(u|t), and
the dashed lines the corresponding 95% confidence intervals.
Figure 7.15 shows the dynamic predictions of the survival probability updated with
each new HHS measurement. We observe that after the second HHS measurement, where
there is a clear increase in HHS, the rate of decrease of the conditional survival function
becomes less steep.
To further examine how changes in the observed HHS measurements effect the dynamic
updates of the survival probabilities we can compare the predictions for two other patients.
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Figure 7.16: Dynamic survival probabilities for Patient 10298 from the THR dataset
during follow-up. The vertical dotted lines represent the time point of the last HHS
measurement. Left of the vertical line, the fitted longitudinal trajectory is depicted.
Right of the vertical line, the solid line represents the median estimator for πi(u|t), and
the dashed lines the corresponding 95% confidence intervals.
Figure 7.16 shows the dynamic survival probabilities for Patient 10298 from the THR
dataset during follow-up. The vertical dotted lines represent the time point of the last
HHS measurement. Left of the vertical line, the fitted longitudinal trajectory is depicted.
Right of the vertical line, the solid line represents the median estimator for πi(u|t), and the
dashed lines the corresponding 95% confidence intervals. It is clear that in comparison to
Figure 7.15 this patient has overall a lower observed HHS. This is reflected in the steeper
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conditional survival function over all time points. This patient is exactly 24 years older
than Patient 10056 which also contributed to the lower survival probability that we see.












































































































































Figure 7.17: Dynamic survival probabilities for Patient 10268 from the THR dataset
during follow-up. The vertical dotted lines represent the time point of the last HHS
measurement. Left of the vertical line, the fitted longitudinal trajectory is depicted.
Right of the vertical line, the solid line represents the median estimator for πi(u|t), and
the dashed lines the corresponding 95% confidence intervals.
Figure 7.17 shows the dynamic survival probabilities for Patient 10268 from the THR
dataset during follow-up. The vertical dotted lines represent the time point of the last
HHS measurement. Left of the vertical line, the fitted longitudinal trajectory is depicted.
Right of the vertical line, the solid line represents the median estimator for πi(u|t), and
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the dashed lines the corresponding 95% confidence intervals. We can see that there is a
decrease in the observed HHS over time for this patient. Therefore, the survival probability
function becomes steeper over time.
These predictions show that it is possible to get accurate dynamic predictions of both
the survival and longitudinal outcomes, that can be used in personalised medical treat-
ment. These predictions are capable of incorporating not only the survival predictions,
and the HHS predictions but also the relationship between these two outcomes.
Overall the longitudinal predictions made using this joint model are more accurate
than those made using the mixed-effects model. Although, one has to be aware of the
limitations of these predictions. In this case, a crucial limitation is that the low HHS
observations are slightly over predicted. Likewise, the higher HHS observations are un-
der predicted. Nevertheless, there are definite advantages to using this model. This
joint model gives dynamic survival probability predictions that can help inform pain and
function prediction. At a more general level, this model provides greater insight into a
patient’s health, as it relates to their THR.
154 Chapter 7. Joint Modelling
Chapter 8
Extension of the Joint Model
In this chapter we explore two extensions of the joint model defined in the previous
chapter. Firstly, we analyse a joint model where the survival outcome is the time until
a patient undergoes their second surgery, instead of survival time. Secondly, we explore
joint modelling with multivariate longitudinal outcomes. We are specifically interested
in the effect of separating the HHS into separate pain and function scores, which in turn
becomes two longitudinal outcomes. We see that combining two important measures,
such as pain and function, into one measure, the HHS, has clear limitations.
8.1 Second Surgery Sub-Study
In the previous section we explored joint modelling of time-to-event and longitudinal
outcomes for the total hip replacement (THR) dataset. Specifically analysing Harris
hip score (HHS) as a longitudinal outcome and survival as the time-to-event outcome.
Alternatively, we can consider the time until a patient undergoes their second surgery
to be the time-to-event outcome. Therefore, we can create a joint model where the
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longitudinal outcome is still the HHS but the time-to-event outcome is a patient’s second
surgery status.
Patient Demographics Second Surgery One Surgery
n of patients 269 1533
Mean (SD) age (yrs) 63.2 (10.6) 67.4 (12.3)
Mean (SD) weight (kgs) 81.3 (16.7) 78.2 (18.2)
Female (n,%) 168 (62.5) 891 (58.1)
Male (n,%) 101 (37.5) 642 (41.9)
Diagnosis (n,%)
AVN 21 (7.8) 125 (8.2)
Number of Comorbidities (n,%)
None 68 (25.3) 411 (26.8)
One 95 (35.3) 525 (34.2)
Two 67 (24.9) 347 (22.6)
Three 27 (10.0) 180 (11.7)
Four or more 11 (4.1) 70 (4.6)
Table 8.1: Summary of the distribution of demographic variables for second surgery and
non-second surgery patients (n = 1802).
When we state that a patient is undergoing a second surgery we are referring to
a patient having surgery on their other hip. For example, if a patient initially has a
THR on their right side then their second surgery would be a left side THR. Within the
THR dataset there are 450 (19.7%) patients who undergo a second surgery. Within this
particular sub-study of 1802 patients there are 269 patients (14.9%) that have undergone a
second surgery. Table 8.1 shows a comparison of the distribution of demographic variables
across patients who have had a second surgery and those that only have one surgery. This
shows that the mean age of patients who have had a second surgery (63 yrs) is lower
than mean age of the whole dataset (67 yrs) and lower than the mean age of the subset
of patients with one surgery (67 yrs). We also note that there is a higher percentage
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of females who have undergone a second surgery when compared to the distribution of
females that have only had one surgery. Nevertheless, the distribution of demographic
variables is relatively consistent across patients who have or have not had a second surgery.
The same joint modelling frame work that was introduced in the Chapter 7 is again




T bi + εi(t),
hi(t) = h0(t) exp
[
γTwi + α{xi(t)Tβ + zi(t)T bi}
]
, t > 0,
where the hazard function, hi(t), refers to the rate of second surgery at a time point.
Initially a joint model was explored where the predictor variables for the longitudinal
sub-model were simply baseline age, gender and follow-up time. For the survival sub-
model baseline age and gender were also included. This joint model showed similar limi-
tations to the initial joint model explored in Chapter 7. For example, there appeared to be
strong systematic trends in the residuals. Therefore, we proceeded to include more predic-
tor variables within the longitudinal sub-model. Specifically, the longitudinal sub-model
was given the same structure as the optimal mixed-effects model identified in Chapter 4.
The predictor variables specified within the time-to-event sub-model are still baseline age
and gender. The joint model that contained a smaller set of predictor variables included
1802 patients, of which approximately 15% had experienced a second surgery. When more
predictor variables were included in the longitudinal sub-model the number of patients
within the estimation model frame became 801, of which approximately 17% have had a
second surgery.
Table 8.2 shows the results of the joint model, with second surgery as the time-to-event
outcome. For both sub-models, estimated parameters, standard errors (SE) and p-values
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Variable Estimate SE p-value
Longitudinal sub-model
Intercept 2.96 0.37 <0.001
Baseline age (years) -0.01 0.004 0.001
Follow-up time 0.02 0.002 <0.001
(Follow-up time)2 -0.0002 0.000 <0.001
Gender 0.41 0.09 <0.001
Weight -0.008 0.002 <0.001
AVN -0.46 0.15 0.002
Number of Comorbidities
One -0.04 0.11 0.73
Two -0.31 0.12 0.01
Three -0.36 0.14 0.008
Four or more -0.39 0.18 0.03
Place of Residence
Home alone & external support -0.45 0.17 0.007
Home with others & independent -0.04 0.10 0.65
Home with others & support -0.54 0.13 <0.001
Other -0.58 0.30 0.05
Smoker (non-smoker)
Moderate -0.46 0.13 <0.001
Heavy 0.25 0.29 0.40
Variable Estimate SE p-value HR
Survival sub-model
logit(HHS) -0.42 0.12 <0.001 0.66
Baseline age (years) -0.03 0.007 <0.001 0.97
Gender -0.29 0.19 0.12 0.75
Table 8.2: Results of the joint model with second surgery as the time-to-event outcome.
For both sub-models, estimated parameters, standard errors (SE) and p-values are re-
ported (n = 1802).
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are reported. The results for the longitudinal sub-model are similar to the results shown in
Table 7.3. Patients with a heavier weight are associated with a decrease in HHS. Suffering
from AVN is associated with a decrease in HHS when compared to not suffering from AVN.
The more comorbidities you suffer from is associated with worse pain and less function.
For the variable place of residence, patients who have external support are again associated
with a decrease in HHS when compared to patients who live independently. Also patients
who smoke moderately are associated with a decrease in HHS when compared to patients
who do not smoke.
For the survival sub-model Table 8.2 shows the hazard ratio (HR) of each predictor
variable. Since a higher HR indicates a higher hazard of having a second surgery we see
that patients who are older are associated with a slightly lower hazard of having a second
surgery. This may be due to it becoming less feasible for patients to undergo a THR on
both the left and right side as they get older.
The association between the transformed HHS and the time-to-event outcome (Table
8.2) is significant and negative. This means that having a higher HHS is associated with
a higher probability of not undergoing a second surgery, which is as expected. Patients
who experience less pain and greater function are less likely to suffer from conditions that
will increase their risk of second surgery.
The diagnostic plots for this model showed many similarities to the model explored in
Section 7.3. While some assumptions of the model appear supported by the diagnostics
there are still some limitations that become evident. Figure 8.1 shows the subject specific
residuals versus the fitted values, the Q-Q plot of the subject specific residuals, and the
marginal survival and cumulative risk functions for the event process. The first plot shows
that those observations where the HHS is 100 behave poorly, otherwise the assumption
of homoscedasticity is valid. The Q-Q plot shows that the assumption of normality is in
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Figure 8.1: Diagnostic plots for the joint model with second surgery as the time-to-event
outcome. Included are the subject specific residuals versus the fitted values, the Q-Q plot
of the subject specific residuals, and the marginal survival and cumulative risk functions
for the event process (n = 1802).
question due to the upper tail deviating from the reference line. Therefore, these results
are similar to those found previously, showing that this model does not appropriately
predict the upper bound of the HHS.
The survival sub-model diagnostics were also explored. For example, Figure 8.2 shows
the Cox-Snell residuals for the survival sub-model. The black solid line denotes the
Kaplan-Meier estimate of the survival function of the residuals (with the dashed lines
corresponding to the 95% point-wise confidence intervals), and the grey solid line, the
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Figure 8.2: Cox-Snell residuals for the survival sub-model. The black solid line denotes
the Kaplan-Meier estimate of the survival function of the residuals (with the dashed lines
corresponding to the 95% point-wise confidence intervals), and the grey solid line, the
survival function of the unit exponential distribution (n = 1802).
survival function of the unit exponential distribution. If this model was appropriate
we would expect to see the Kaplan-Meier estimate close to the survival function of the
unit exponential distribution, as this is the expected asymptotic distribution. Though
it is clear that there are some differences in these lines the survival function of the unit
exponential distribution lies close to the 95% point-wise confidence interval. We also note
that because in this case our time-to-event outcome is undergoing a second surgery the
survival probabilities are overall higher. This implies that there is a higher probability
that a patient will not have a second surgery in comparison to the probability that a
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patient will survive (see Figure 7.6).
Overall, this joint model shows that the variables age, gender, follow-up time, weight,
suffering from AVN, number of comorbidities, place of residence and smoking status are
all significant predictor variables for the HHS. Not only are they capable of predicting a
patient’s HHS but their HHS prediction is also capable of informing a patient’s survival
status or risk of second surgery.
Dynamic prediction using this joint model is possible but will not be explored here.
Instead, we now consider separating the HHS into a pain score and function score. This
is due to our interest in the separate prediction of pain and function. Therefore, we want
to explore if it is more informative to predict pain and function separately instead of
together within the HHS.
8.2 Joint Model with Multivariate Longitudinal Out-
comes
Another extension of the joint model is joint models with multivariate longitudinal out-
comes. This means considering pain and function as separate longitudinal outcomes. To
begin this analysis each patient’s pain and function scores had to be calculated. In this
case, the pain score is defined as the answer to the first question in Table A.2 in Appendix
A.2. The question is how much pain is the patient in. There are six possible answers
with the highest scoring answer (score of 44) indicating that the patient is not in pain.
We note that this variable, pain score, is more appropriately dealt with as a categorical
variable but this is outside of the scope of this study. Therefore, we explore modelling
with the assumption that the pain score is a continuous variable. The function score
8.2. Joint Model with Multivariate Longitudinal Outcomes 163
will be defined as all other components of the HHS, including the four points that assess
if there is an absence of deformity (see Tables A.2, A.3 and A.4 in Appendix A.2). To














Figure 8.3: Side-by-side boxplot of the patient baseline age against pain score (n = 1796).
This joint modelling analysis with multivariate longitudinal outcomes will only address
the predictor variables age, gender and follow-up time as this is merely foundational work.
As a result, this analysis includes 1796 patients, as these variables contain little to no
missingness. Figure 8.3 shows a side-by-side boxplot of the age of patients against the
pain score. This shows that there is not significant change in age distribution as a patient’s
pain increases. There are also more young patients, evident in the outliers, as the pain
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score increases. This implies that patient’s who are younger, and are outliers in the age
















Figure 8.4: Side-by-side boxplot of the function score against the pain score for THR
patients (n = 1796).
Figure 8.4 shows a side-by-side boxplot of the distribution of the function score against
the pain score. It is clear from this plot that a patient who experiences greater pain
is more likely to have poor function, and the converse is also true. Though there are
some exceptions, as seen in the outliers, the medians show a clear increase in pain as
function worsens. Therefore, there appears to be a linear relationship between these two
longitudinal outcomes.
After completing univariate and bivariate analysis of both the pain and function out-
comes we now proceed to modelling these outcomes separately, before exploring joint
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modelling. A mixed-effects model frame work was used to model both the pain and func-
tion outcomes separately. The only predictor variables included were baseline age, gender
and follow-up time. The optimal random effects structure was determined using the same
model selection process shown in Chapter 4. Therefore, the random effects structure was
determined first and the fixed effects structure was unchanged. This was done to keep
the predictor variables across all sub-models the same as this is a preliminary model.
The two mixed-effects models, one with the pain score as the outcome and the other
with the function score as the outcome, can be written as
PainScoreij = α + β1Sexi + β2Agei + β3FollowupTimeij+
bi0 + bi1FollowupTimeij + εij.
FunctionScoreij = α + β4Sexi + β5Agei + β6FollowupTimeij+
bi0 + bi1FollowupTimeij + εij.
where the term bi0 is the random intercept and bi1 is the random slope for follow-up
time. Therefore, the optimal random effects structure for both the pain and function
score mixed-effects models included random slopes and intercepts. The estimated param-
eters for these models are calculated using REML and are shown in Table 8.3. We note
that in this model, the correlation between the outcomes and survival endpoint are not
incorporated into the random effects and so are difficult to interpret.
In relation to the pain score, Table 8.3 suggests that being male is associated with
less pain. The variables follow-up time and age are not significant within this model.
The variability of the intercept across patients has a standard deviation of 6.70, while
8.34 is the standard deviation of the variability within patients. This suggests that the
mixed-effects model is potentially accounting for the correlations within patient repeated
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Pain Score Function Score
Parameter Estimate p-value Estimate p-value
Fixed Effect Intercept (score 34.01 <.0005 47.45 <.0005
Estimates at 0 months)
Slope (months) -0.005 0.24 -0.009 0.02
Sex 1.05 0.01 3.40 <.0005
Age 0.03 0.08 -0.15 <.0005
Standard Deviation
Component of Within Patient Residual 8.34 6.22
Variance Between Patient Residual 6.70 8.68
Estimates (intercept)
Between Patient Residual 0.05 0.06
(slope)
corr(bi0, bi1) -0.21 -0.34
Table 8.3: Estimated model parameters for pain and function score mixed-effects models.
For both models, estimated parameters, p-values, and components of variance estimates
are reported (n = 1796).
measurements. There is a negative correlation between the intercept and slope. This
implies that when a patient’s intercept increases by one unit of standard deviation, that
patient’s slope decreases by 0.21 standard deviations. Though this sub-model is not
optimal, for the purpose of exploring an extension of joint modelling, it is sufficient.
In relation to the function score, Table 8.3 suggests again that being male is associated
with better function. This model suggests that follow-up time after surgery is associated
with a decrease in function score. Patients who are older are also associated with worse
function than younger patients. The within patient variability is smaller than the inter-
cept variability. The correlation between the intercept and the slope is again negative.
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This suggests that a patient that starts with better function is associated with a more
negative slope or trajectory than a patient of the same characteristics who starts with
worse function.
Up until this point we have only addressed univariate joint modelling. Nevertheless re-
cent work in the field of joint modelling has provided new ways to address the application
of multivariate joint models. Specifically the work done surrounding the joineRML pack-
age will be explored and applied in this section. This package implements a multivariate
joint model that is an extension of the classical model for the multivariate longitudinal
outcomes case and is described by Hickey et al. [14]. The implementation of this model
relies on an algorithm proposed by Lin et al [18] with some changes to decrease com-
putational time. These alterations include a quasi-Newton update approach, variance
reduction method and dynamic Monte Carlo updates. What follows is a summary of the
theory used to implement this joint model.
Let’s suppose we have k longitudinal outcomes. For each subject i = 1, . . . , n the vector
of longitudinal outcomes is yi = (y
T
i1, . . . ,y
T
iK), where yik is the observed measurements
for the k-th longitudinal outcome. Therefore, each measurement is recorded at time tijk,
where j is the number of observations recorded for each patient. As with previous joint
models, T ∗i is the time as which the event occurs. Due to potential censoring the observed
event time is Ti = min(T
∗
i , Ci), where Ci is the censoring time (in this case the end of
2013).
As with the joint model formulation shown in Chapter 7 these two separate sub-
models, longitudinal and survival, are linked using association parameters. This model
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which is a (K+1)-variate Gaussian process with mean zero. This process is determined






1i (t) + εik(t)
where xTik(t) is the vector of covariates and βk are the fixed effects parameters for the
covariates. W
(k)
1i (t) is defined as
W
(k)
1i (t) = z
T
ik(t)bik,
where zTik(t) is the vector of covariates and bik is the corresponding random effects for
the i-th subject relating to the k-th outcome. bik has a multivariate normal distribution
with mean zero. The variance-covariance matrix for this term is Dkk. To address the
dependance between multiple longitudinal outcomes we specify that cov(bik, bil) = Dkl
for k 6= l. Similarly as before, we assume that the error terms, εik(t), and the random
effects terms, bik, are uncorrelated.
It is also necessary to specify the survival sub-model. This can be written as





where vTi (t) is the covariates associated with the hazard, γv is the vector of regression
coefficients and h0(t) is the baseline hazard. This hazard model is conditional on both
Wi(t) and the inputed covariate data. Therefore, the longitudinal and time-to-event
processes are conditionally independent. To create the desired latent association we define
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where γy are the association parameters. In our case, k is two as there are two
longitudinal outcomes, pain score and function score. The latent process that links our
sub-models is
Wi(t) = {W (1)1i (t),W
(2)
1i (t),W2i(t)}
where k can take the values one or two. Therefore, the joint model for multivariate






1i (t) + εik(t),






where W2i(t) = γy1W
(1)
1i (t) + γy2W
(2)
1i (t) and the variables used are outlined previously
in this section. This model is then estimated using likelihood estimation and the Monte
Carlo Expectation Maximisation algorithm (MCEM). MCEM effectively determines the
maximum likelihood estimates of the parameters through addressing the random effects
as missing data [32].
Therefore, a joint model with multivariate longitudinal outcomes, namely pain score
and function score, and survival outcome was analysed using the joineRML package [14].
The results of this joint model are shown in Table 8.4. Since this is a preliminary model the
results shown are limited, nevertheless they are still of interest. It is clear that for both the
pain and function scores, being male is associated with a higher score, meaning less pain
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and greater function. Interestingly, the variable follow-up time is not significant within the
pain score sub-model. However, follow-up time is significant within the function score sub-
model, suggesting that greater time after surgery is associated with worse function. The
variable age is not significant within the pain score sub-model but it is highly significant
within the function score sub-model. The older a patient is the higher their association
with a worse function score.
Longitudinal sub-model
Outcome Variable Estimate SE p-value
Pain Score Intercept 34.14 1.26 <0.001
Baseline age (years) 0.03 0.02 0.11
Follow-up time -0.0047 0.0057 0.40
Gender 1.10 0.45 0.01
Function Score Intercept 47.48 1.32 <0.001
Baseline age (years) -0.15 0.02 <0.001
Follow-up time -0.009 0.004 0.04
Gender 3.45 0.48 <0.001
Survival sub-model
Variable Estimate SE p-value HR
Pain Score 0.07 0.02 <0.001 1.08
Function Score -0.11 0.01 <0.001 0.90
Baseline age (years) -0.02 0.005 <0.001 0.98
Gender -0.18 0.13 0.17 0.84
Table 8.4: Results of the joint model, which includes multivariate longitudinal outcomes.
For both sub-models, estimated parameters, standard errors (SE) and p-values are re-
ported (n = 1796).
The results of the survival sub-model, Table 8.4, also show further insights into the
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pain and function scores in relation to a patient’s survival probability. In this joint model
gender does not appear to be a significant predictor of survival. Interestingly, this survival
sub-model suggests that older patients are slightly associated with a lower hazard of death
than younger patients. We also see that patients who experience better function have a
lower hazard of death, as the HR for function score is less than one. This may be because
mobility and function is often a reflection of greater holistic health. In relation to the
pain score, patients with worse pain are associated with a lower hazard of death. This
implies that a better pain score does not increase survival probability the same way that
an increased function score does. This result may be explained by the fact that regression
associations often do not imply causal relationships [5]. Alternatively, patients with high
levels of pain may have been a priority for treatment, decreasing their hazard of death.
Our aim in this section was to present an introductory analysis using the joint mod-
elling with multivariate longitudinal outcomes approach. There are limitations to this
implementation. For example, the joineRML package only allows an association struc-




1i (t), though this association may take different forms. This
model also does not account for a potential interaction between the longitudinal outcomes,
pain and function score, within the hazard sub-model. Nevertheless, there is ongoing work
occurring in this area to address the gap that the package, and research around, joineRML
has begun to fill.




In this thesis we have investigated how to predict postoperative patient pain and function
based on preoperative factors, such as age and gender, for total hip replacement (THR)
patients. Previous analyses into patient recovery from THR are not in terms of subjective
reports of symptomatic relief, such as the Harris hip score (HHS). Likewise, the increased
risk of patient outcomes after THR due to comorbidities is not always addressed. Both
of these concepts are addressed in a thorough exploration of the methods used to model
longitudinal data. This exploration displayed several interesting results.
Using mixed-effects modelling, where the response variable was the HHS, we deter-
mined that suffering from comorbidities is associated with a lower HHS after THR surgery.
This required a logit transformation of the HHS that behaved poorly at the upper bound,
100, throughout the analysis. The process of model selection showed that random in-
tercepts, for each patient, and random slopes was the optimal random effects structure.
Therefore, there is a relationship between HHS and follow-up time which is different for
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each patient. In addition, patients who require external support before undergoing a
THR are also associated with a lower HHS, in comparison to patients who do not require
external support and patients who are older and heavier are also associated with a lower
HHS after THR surgery.
The best prediction, for the optimal mixed-effects model, occurs for patients who exist
within the estimation model frame making it optimal to have at least one HHS measure-
ment to perform prediction. This was determined through an exploration of different
methods of prediction for this model. For existing patients the best prediction utilised
the best linear unbiased predictions (BLUPs) of the random effects of that patient. For
new patients, those not within the estimation model frame, the best prediction required
using the BLUPs of the random effects of patients with similar characteristics to the new
patient. Nevertheless, if the sample size is not large enough to have a number of patients
with similar characteristics, then using an average patient’s BLUPs of the random effects
is optimal.
Building on our previous results, we were able to predict whether a patient will ex-
perience any improvement in HHS at 24 months after surgery. This was done using a
mixed-effect models with a new response variable, change in HHS, using baseline HHS
measurements. For the majority of patients there is an overall improvement in HHS, for
some this is not the case.
Within survival analysis, the number of comorbidities that a patient suffered from
again proved to be significant. A patient with no comorbidities is associated with a
significantly higher survival probability than a patient with any other number of comor-
bidities. Due to a large proportion of THR patients within this dataset who were deceased,
survival status could also be applied as a survival outcome within joint modelling.
Joint modelling allowed us to perform dynamic prediction, a valuable tool for per-
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sonalised medicine, using the foundation obtained from the separate longitudinal and
survival analyses. We obtained the most appropriate joint model by including the previ-
ous optimal mixed-effects model predictors in the longitudinal sub-model. Joint modelling
confirmed previous results, such as the association between comorbidities and HHS af-
ter THR surgery, but also allowed us to use dynamic prediction. Therefore, for specific
patients, we can see how predictions relating to both the HHS and survival outcome are
updated as new information is inputed.
Joint modelling was also applied where the survival outcome was second surgery. The
results showed that patients who experience a lower HHS are more likely to undergo a
second surgery. The longitudinal fixed effects results supported the results obtained in
the previous joint model.
Despite our previous findings, analysis of pain and function separately provided more
insight than when combining them into the HHS. This has important implications for the
interpretation and application of results based on the HHS. Although pain and function
were significantly correlated and had a joint predictor of sex when analysed separately,
joint modelling revealed different predictors for each. In addition, with the survival sub-
model, greater function lowered the hazard of death while less pain was associated with
an increased hazard.
9.1.1 Future Work
An approach that was not explored within this study was greater scale imputation.
Though some variables were imputed there were variables that were not imputed that
contained missingness. This missingness in turn effected the sample size that could be
used to create a certain model. Therefore, further work into appropriately imputing this
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dataset would be valuable and help utilise all patient information.
The joint model with multivariate longitudinal outcomes relied on the package join-
eRML. For this method to be more widely used, it needs to have more flexible association
structures and allow for interactions between longitudinal outcomes within the hazard
sub-model. Therefore, further work in this area would be an invaluable place to start.
Future research could expand the scope of the survival analysis that was completed.
Specifically, to improve the joint modelling performed more time could be spend under-
standing the appropriate predictor variables to predict the survival risk of a patient. In
this research only a simple survival sub-model was used that contained age, gender and
follow-up time. Futhermore, all results were obtained using ML estimation, therefore
Bayesian inference could also be explored using the R package JMbayes.
Within this thesis we have assumed that both the pain score and function score are
continuous quantitative variables. In both cases these variables could be considered or-
dinal categorical variables as they are the summation of discretely answered questions in
a questionnaire. Therefore, more time could be spent exploring the results of modelling
these outcomes as ordinal categorical rather than continuous quantitative variables to see
if this increases predictive accuracy.
Finally, we consider the purpose of this thesis to be twofold. Firstly, this research identifies
some key variables that are significantly and consistently associated with worse pain and
function after THR surgery. Therefore, this information can inform clinicians to encourage
potential changes in their patients before undergoing THR to improve pain and function
outcomes. For example, the number of comorbidities that a patient suffers from is a
significant predictor across all longitudinal models. This means that comorbidities are
shown in this research to have a direct effect on the pain and function of a patient after
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THR surgery. Therefore, if a patient presents for a THR and suffers from a large number
of comorbidities it is important to ensure that these comorbidities are being treated and
addressed before undergoing surgery.
Secondly, this thesis outlines a process that can be used to obtain predictions relating
to joint pain and function measurements after THR surgery. It also clearly outlines the
limitations of these predictions to ensure careful interpretation of the results. These
models can be used to predict a patient’s potential pain and function at two years after
THR surgery, at which point there should be a resolution of symptoms. The dynamic
prediction, used in conjunction with joint models, allows for updating predictions that
can inform the clinician of any changing or negative pain and function trajectories so that
intervention can occur. This can then inform clinicians of the best way to address the
health of a specific THR patient.
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Appendix A
Appendix
A.1 Summary of Variables Within the THR Dataset
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Dataset Name Description (units) Type
Demographic age age at operation (years) integer
gender gender of patient 1=male, 2=female
dob date of birth (dd/mm/yyyy) date
status survival status categorical
dod date of death (dd/mm/yyyy) date
Employment employ employment catgorical
emp oth specified other employment status free text field
occ desc occupation description free text field
profile profile free text field
Lifestyle smoker current cigarette/tobacco smoker 1=no, 2=yes, 999=not known
cig day number of cigarettes per day free text field
alcohol current alcohol consumption 1=no, 2=yes, 999=not known
alc day number of standard drinks per day free text field
soc drgs social drugs 1=no, 2=yes, 999=not known
drgs sp social drugs specified free text field
Residence plc res place of residence categorical
pr oth other place of residence specified free text field
hm alone specify if living at home alone categorical
hm others specify if living at home with others categorical
nrsh dt date entered nursing home free text field
Past medical pmh inactive past medical history 1=no, 2=yes, 999=not known
history pmh spec inactive past medical history specified free text field
oth maj other major orthopaedic/musculoskeletal conditions 1=no, 2=yes, 999=not known
om spec other major orthopaedic/musculoskeletal conditions specified free text field
Previous Operation prev op previous operations/complications in this area/joint 1=no, 2=yes, 999=not known
op desc previous operation description free text field
op yr previous operation year numeric
op hosp hospital of previous operation categorical
op month previous operation month numeric
op4prev previous surgery 2=yes, 1=no
op4num number of previous surgeries integer
op4plast last type of surgery free text field
op4lstyr last year of surgery (yyyy) integer
Illness curr med current medications 1=no, 2=yes, 999=not known
cmed sp current medications specified free text field
Comorbidities comorbs comorbidities 1=no, 2=yes, 999=not known
co morb cormorbidities categorical
com spec comorbidities specified free text field
Surgery pat id patient id numeric
adm no admission number numeric
Diagnosis op4jdoa diagnosis is osteoarthritis 2=yes, 1=no
op4jdra diagnosis is rheumatoid arthritis 2=yes, 1=no
op4jd1cs osteoarthritis is secondary to 3=dysplasia, 4=trauma, 5=other diagnosis
op4jd1oc other diagnosis (in relation to op4jd1cs) free text field
op4AVN diagnosis is avascular necrosis 2=yes, 1=no
op4jdsot diagnosis is another joint disease free text field
op4fra diagnosis is neck of femur fracture 2=yes, 1=no
op4fcoth other fracture diagnosis free text field
op4othsp other diagnosis specified free text field
adm diag admission diagnosis free text field
other diag all other diagnosis specified free text field
hist cmp history of presenting complain free text field
Operation adm date admission date (dd/mm/yyyy) date
op1opdte operation date (dd/mm/yyyy) date
op4side joint side 1=left, 2=right, 3=bilateral
Implant op5acnme name of acetabulum implant categorical
op5acss survival of acetabulum implant categorical
op5fnme name of femoral implant categorical
op5fss survival of femoral implant categorical
Follow-up* form date form date (dd/mm/yyyy) date
fuptime follow-up time (months) numeric
fuptimeyrs follow-up time (years) numeric
htrend trendelenburg test categorical
hlurch lurch 1=no, 2=yes, 999=not known
hlength leg length 1=equal, 2=short, 3=long, 999=not known
hdist leg length measurement (cms) numeric
Power hflexpw flexion categorical
habdpw abduction categorical





hextint1 external rotation categorical
hextint2 internal rotation categorical
Pain pain pain from hip categorical
hsrcbck other sources of pain referred to the high/thigh region 1=no, 2=yes, 999=not known
hsrcoth other sources of pain referred to the high/thigh region specified free text field
hstress pain on stressing the hip or extremes 1=no, 2=yes 999=not known
htender tenderness categorical
htenderother tenderness specified free text field
Mobility mob abhs able to get around the house categorical
mob outh able to get out of the house categorical
mob shop able to go shopping categorical
Scores harris harris hip score numeric
charnley charnley score numeric
Complications and hcomp complications since last hip surgery 1=no, 2=yes, 4=NA, 999=not known
Dislocations hcompsp complications since last hip surgery specified free text field
hdislcn number of dislocations since surgery 0=Nil, 1=1, 2=2, 3=>2, 999=not known
hdisyr year of dislocations (yyyy) numeric
Notes alerts alerts free text field
auditnotes notes free text field
Table A.1: Table of Variables contained within the Total Hip Replacement dataset; * repeated measurements.
A.2 Harris Hip Score Calculation
The equation used to calculate the Harris hips score is as follows:
Harris hip score = (pain value) + (limp value) + (support value) + (distance walked
value) + (stairs value) + (shoes value) + (sitting value) + (public transportation value)
+ (absence of deformity value) + (range of motion value).
The overall score for the range of motion is calculated as follows:
Range of motion value = (SUM((value) × (index factor))) × 0.05.
This scoring system allows for a maximum of 100 points (pain 44 function 47 absence
of deformity 4 range of motion 5). To calculate the value of (pain value) + (limp value)
+ (support value) + (distance walked value) + (stairs value) + (shoes value) + (sitting
value) + (public transportation value) use Table A.2. To calculate the score for the
absence of deformity use Table A.3. And lastly to calculate the score for the range of
motion use Table A.4.
Variable (column Categories Value in Equivalent value
name) dataset for HHS
pain (parhpain) none or ignore it 44 44
slight, occasional pain 40 40
mild plain 30 30
moderate pain 20 20
marked pain, severe at times 10 10
totally disabled, crippled by pain 0 0




unable to walk without support 5 0
support (pasupp) none 1 11
walking stick for long walks 2 7
walking stick most of the time 3 5
one crutch 4 3
two walking sticks 5 2
two crutches 6 0
frame 7 0
not able to walk 8 0
walk (pawalk) unrestricted distance 1 11
greater than 10 blocks 2 8
five to six blocks 3 8
two to three blocks 4 5
less than one block 5 5
housebound 6 2
wheelchair bound 7 0
bedridden 8 0
stairs (pastair) normally, without using railing 1 4
normally, with railing or device 2 2
two feet on each step 3 1
any other method 4 1
unable to 5 0
shoes (pashoe) no difficulty 1 4
some difficulty 2 2
unable to 3 0
sitting (pasit) in ordinary chair, for one hour 1 5
in a high chair, for half an hour 2 3
unable to sit comfortably 3 0
public transport yes 1 2
(papublic) no 2 1
Table A.2: Pain calculation for HHS table.
Variable (column name) All of the following must be present 4 points
flexion (hflexn1&hflexn2) < 30o fixed flexion contracture
abduction (habd1) < 10o fixed adduction
internal rotation in extension < 10o fixed internal rotation in extension
(hextint2)
limb-length discrepancy (hdist) limb-length discrepancy < 3.2cm
Table A.3: Absence of deformity calculation for HHS table.
Variable (column name) Range (degrees) Values Index factor
in dataset
flexion (hflexn1&hflexn2) 0-45 0-45 1.0
45-90 0-45 0.6
90-110 0-20 0.3
abduction (habd1) 0-15 0-15 0.8
15-20 0-5 0.3
> 20 0
external rotation in extension (hextint1) 0-15 0-15 0.4
>15 0
internal rotation in extension (hextint2) any 0
adduction(habd2) 0-15 0-15 0.2
Table A.4: Range of motion calculation for HHS table.
A.3 Summary of Variable Relabellings and Changes
Variable (column name) Regrouping Levels
Medications (cmed sp) Paracetamol Paracetomol
Paracetamol Immune System Supplement
Acetaminophen NSAID’s, non-selective cox
Panadol inhibitor
Immune System Supplement NSAIDs, cox 2 inhibitors
Methotrexate Opioids, weak

























Employment Specified Free text field Disability Pension
(emp oth) No Disability Pension
Smoker (smoker & Non-smoker Non-smoker
cig day) No (smoker) Light smoker
Light Smoker Heavy smoker
Yes (smoker, unspecified cig day)
< 25 a day (cig day)
Heavy smoker
≥25 a day (cig day)
Alcohol (alcohol & Non-drinker Non-drinker
alc day) No (alcohol) Light/Moderate Drinker
Light/Moderate Drinker Heavy Drinker
Yes (alcohol, unspecified alc day)
< 6 a day (alc day)
Heavy Drinker
≥6 a day (alc day)
Social Drugs Specified Free text field No Marijuana
(soc drgs) Marijuana
Residence (plc res & Home Alone & Independent Home Alone & Independent
hm alone & hm others) Home Alone (plc res, unspecified Home Alone & External
hm alone) Support
Independent (hm alone) Home with others &
Home Alone & External Support Independent
External Support (hm alone) Home with others & Support
Home with others & Independent Other
Home with others (plc res,
unspecified hm others)
Independent (hm others)
Home with others & Support
Dependent (hm others)
External Support (hm others)
Other
Nursing Home (plc res)
Other (plc res)
Survival of Implant Revised Revised
(op5acss & op5fss) Revised Unrevised








Implant Name (op5acnme Trilogy & CPT Trilogy & CPT
& op5fnme) Trilogy (op5acnme) Exeter & Exeter or Vitalock
CPT (op5fnme) & Exeter
Exeter & Exeter or Vitalock Other
& Exeter
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